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ABSTRACT

Ovarian cancer is the most lethal gynecological cancer, with over 200,000
women diagnosed each year and over half of those cases leading to death. These poor
statistics are related to a lack of early symptoms and inadequate screening techniques.
This results in the cancer going undetected until later stages when the tumor has
metastasized through a process that requires the epithelial to mesenchymal transition
(EMT). In lieu of traditional monolayer cell culture, EMT and cancer progression in
general is best characterized through the use of 3D spheroid models. In this study, we
examine gene expression changes through microarray analysis in spheroid versus
monolayer ovarian cancer cells treated with TGFβ to induce EMT. Transcripts that
included Coiled-Coil Domain Containing 80 (CCDC80), Solute Carrier Family 6 (Neutral
Amino Acid Transporter), Member 15 (SLC6A15), Semaphorin 3E (SEMA3E) and PIF1
5'-To-3' DNA Helicase (PIF1) were downregulated more than 10-fold in the 3D cells
while Inhibitor Of DNA Binding 2, HLH Protein (ID2), Regulator Of Cell Cycle (RGCC),
Protease, Serine 35 (PRSS35), and Aldo-Keto Reductase Family 1, Member C1
(AKR1C1) were increased more than 50-fold.
Interestingly, stress responses and epigenetic processes were significantly
affected by 3D growth. The heat shock response and the oxidative stress response
were also identified as transcriptome responses that showed significant changes upon
3D growth. Subnetwork enrichment analysis revealed that DNA integrity (e.g. DNA
viii

damage, genetic instability, nucleotide excision repair, and the DNA damage checkpoint
pathway) were altered in the 3D spheroid model. In addition, two epigenetic processes,
DNA methylation and histone acetylation, were increased with 3D growth. These
findings support the hypothesis that three dimensional ovarian cell culturing is
physiologically different from its monolayer counterpart.
The proteotoxic stress-responsive transcription factor HSF1 is frequently
overexpressed in a variety of cancers and is vital to cellular proliferation and invasion in
some cancers. Upon analysis of various patient data sets, we find that HSF1 is
frequently overexpressed in ovarian tumor samples. In order to determine the role of
HSF1 in ovarian cancer, inducible HSF1 knockdown cell lines were created. Knockdown
of HSF1 in SKOV3 and HEY ovarian cancer cell lines attenuates the epithelial-tomesenchymal transition (EMT) in cells treated with TGFβ, as determined by western
blot and quantitative RT-PCR analysis of multiple EMT markers.
To further explore the role of HSF1 in ovarian cancer EMT, we cultured
multicellular spheroids in a non-adherent environment to simulate early avascular
tumors. In the spheroid model, cells more readily undergo EMT; however, EMT inhibition
by HSF1 knockdown becomes more pronounced in the spheroid model. These findings
suggest that HSF1 is important in the ovarian cancer TGFβ response and in EMT.
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CHAPTER ONE: INTRODUCTION

Ovarian Cancer
In the United States, an estimated 22,280 new cases of ovarian cancer will
emerge and 14,240 deaths will occur in 2016, making ovarian cancer the fifth leading
cause of cancer deaths in women [2]. Despite research efforts, ovarian cancer is still
the most lethal gynecological malignancy [2]. This is due to several factors, including
inadequate screening techniques, the absence of early stage symptoms, insufficient
chemotherapy options, and the molecular heterogeneity found in ovarian tumors [4].
Ovarian cancer’s high molecular heterogeneity is due to the large tumor volume, often
several cubic centimeters, found in most patients who present with the disease [5].
Each cubic centimeter may be composed of up to a billion cells, indicating a high
number of cell divisions which leads to high molecular and genetic heterogeneity. The
number of cancer cells and how long they have been present are directly related to the
patient’s probability of chemotherapy resistance through the development of resistant
clone cells [6].
Due to a lack of early symptoms, ovarian cancer is commonly referred to as a
silent disease. Some patients may experience abdominal pain, swelling,
gastrointestinal distress, abnormal vaginal bleeding, appetite changes, frequent
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urination, and/or fatigue [7]. Commonly, patients will experience little to no symptoms
until the cancer has metastasized and is affecting other organs. Current screening
techniques include pelvic examination, ultrasound, computed tomography (CT)
scanning, magnetic resonance imaging (MRI), and CA-125 blood testing [8]. The CA125 serum tumor marker is elevated in 80% of epithelial ovarian cancers and is
detected by a radioimmunoassay [9]. Unfortunately, only half of stage I patients have
significantly elevated levels of this marker [10]. This, in addition to the fact that CA-125
levels are also elevated in many cancer-free women, makes it an inadequate screening
technique [10].
Carcinogenesis is described as the process in which a sufficient number of
somatic mutations occur within a single cell to cause molecular modifications which
yield a malignant phenotype [11]. The first phase of this step-wise process is initiation,
where DNA damage occurs. Second, the precancerous cells continue to proliferate and
accumulate genetic alterations in the step known as promotion. Lastly, progression is
considered the last phase in which these alterations lead to the transformation to
malignant cells.
A number of factors contribute to a patient’s likelihood of developing ovarian
cancer. It has been proposed that incessant ovulation may lead to genetic damage
which could cause ovarian cancer in some women [12]. For instance, the use of oral
contraceptives (OC), child-bearing, breastfeeding, and a healthy weight all reduce a
woman’s risk of presenting with the disease [13]. Contradictory to the incessant
ovulation theory is the finding that taking OCs for three years, only inhibiting ten percent
of lifetime ovulation cycles, reduces the risk of ovarian cancer by as much as fifty
2

percent [14]. Likewise, a single pregnancy is linked to a thirty-five percent reduction
[15]. Studies such as these indicate that ovarian biology, including ovarian cancer risk,
may be greatly affected by the patient’s hormonal balance. Receptors for estrogen,
progestin, androgens, vitamin D, and retinoids are all present in the ovarian epithelium.
During normal pregnancy, women express high levels of progestin which induces
apoptosis and may be the underlying cause for the subsequent reduction in ovarian
cancer risk [16]. In fact, Rodriguez et al. showed that primates treated with estrogen or
progestin presented with a six-fold increase in ovarian epithelium cell apoptosis for
progestin-only subjects [17]. Contraceptives containing progestin only do not
dependably deter ovulation which again does not support the incessant ovulation theory
[18]. Markedly, androgens, however, may have stimulatory effects leading to an
increased risk of ovarian cancer [19]. These studies support the theory that ovarian
cancer develops from the ovarian epithelium’s response to the individual’s hormone
expression.
Genes also play a role in the risk equation. Hereditary genetic mutations are
seen in about ten percent of ovarian cancer patients, wherein lifestyle choices may have
little effect on the outcome [20]. Research has shown that two genes commonly
associated with hereditary types of breast cancer, BRCA1 and BCRA2, are also linked
to a greater chance of ovarian cancer [21, 22]. PTEN, a tumor-suppressor gene, is
frequently mutated in endometrioid ovarian cancer, but PTEN mutation is not seen in
other histological subtypes, indicating that the cancer develops through separate distinct
pathways [23]. It has also been shown that the HER2 oncogene is overexpressed in
nearly thirty percent of ovarian cancers that are linked to poor prognosis [24, 25].
3

Approximately 90% of ovarian cancers develop in the epithelium, while the
remaining cases originate from germ or stromal cells. The major morphological
subtypes of epithelial ovarian cancer include serous, clear cell, mucinous, and
endometrioid [26]. Recent research has shown that accurate pathological typing is
imperative to successful treatment, as each subtype independently responds to therapy
and may indicate underlying genetic conditions [27-29]. These tumors are
characterized as benign, malignant, or intermediate/borderline. Surface epithelial
tumors can be further categorized into type I or type II based on their tumorigenesis
pathways [27]. This categorization is based on broad tumor development mechanisms
to be used in conjunction with the above histological subtypes. Type I tumors are
typically described as low-grade neoplasms which arise from borderline tumors and
type II tumors are high-grade neoplasms with de novo development [27].
Ovarian Cancer Treatment
Upon diagnosis, patients may undergo a series of treatment options to include
surgery, chemotherapy, and in rare cases, radiation. Surgical procedures may aim to
remove the uterus via a hysterectomy, the ovaries and fallopian tubes through a
bilateral salpingo-oophorectomy, the omentum, and/or other affected tissues and
organs [30].
Once surgery is complete, patients typically receive a combinational approach to
chemotherapy utilizing a platinum-based medication such as carboplatin or cisplatin
with a taxane such as paclitaxel or docetaxel. Increased survival rates have been
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shown in women whose drugs are administered in an amalgamation of intravenous and
intraperitoneal injections [31]. Platinum-based medications have a cytotoxic effect
through several cellular events, the most important being DNA platination. DNA
platination is a specific cross-linking event which occurs when the platinum compound
reacts with the N(7) of guanine. Conversely, taxane chemotherapy agents utilized for
ovarian cancer treatment induce cell cycle arrest, and consequentially apoptosis, by
stabilizing microtubules through preventing depolymerization. However, both
medications are accompanied by an array of side effects to include dose-limiting
nephrotoxicity, ototoxicity, dizziness, blurred vision, nausea, painful urination, and
vomiting.
Although most patients respond to platinum and taxane chemotherapeutic agents
at first, the relapse rate is roughly 85% [32]. Ovarian cancer recurrence is seen when
cancerous or precancerous cells remain after treatment and eventually proliferate into a
tumor. Once relapse occurs, it is not unusual for patients to no longer respond to
traditional chemotherapy, as a resistance is developed to the previously exposed
medications. At this stage, supplementary treatment options include topotecan,
hormones, additional surgery, and experimental agents [33]. Topotecan induces
apoptosis by intercalating between the topoisomerase-I cleavage complex and DNA,
thereby leading to an accumulation of double stand DNA breaks. Hormone therapy
may also be utilized to reduce estrogen and increase progesterone levels, which has an
inhibitory effect on cancer proliferation. Even with these alternate treatment routes,
relapse rates are still staggering and most patients with advanced ovarian cancer
succumb to their disease within five years of initial diagnosis [34].
5

Epithelial Mesenchymal Transition
The epithelial to mesenchymal transition (EMT) was first described by Greenburg
in 1982 as a distinct process wherein “cuboidal” epithelial cells undergo changes to
adopt an elongated mesenchymal phenotype (Fig. 1.1) [35]. EMT is most commonly
observed during metazoan embryonic development when epithelial cells must migrate
and dedifferentiate, such as during the formation of the mesoderm layer during
gastrulation [36]. Processes such as gastrulation and neural crest formation are
examples of primary developmental EMTs while secondary developmental EMT is
implicated in organogenesis [37]. Equally as important in embryogenesis is the

Figure 1.1: TGFβ Induction of Epithelial to Mesenchymal Transition.
Addition of TGFβ to epithelial cells promotes their transition to a mesenchymal phenotype
through expression of mesenchymal proteins. This disrupts cell-cell and cell-extracellular
matrix connections to allow the cells to disengage from the tumor and metastasize to other
organs. In ovarian cancer patients, these separated cells can be found free floating within
the peritoneal cavity, making organs such as the stomach, liver, and kidneys prime locations
for secondary tumors. (Adapted from Palena et al., 2011). (Figure created by Trillitye
Paullin).
6

mesenchymal to epithelial transition (MET) which is the reverse process of EMT [38].
This advancement in embryogenesis allowed for higher organism complexity from
diploblastic to triploblastic embryos [35]. In addition to development, EMT is also vital
for wound healing and tissue regeneration. During this processes, EMT is associated
with inflammation and is induced by a repair response in order to reconstruct tissues
[39].
EMT is tightly regulated by a number of genes. Specifically, downregulation of Ecadherin is considered a hallmark for this process and one of the most studied EMT
markers [40]. The protein is responsible for epithelial cell-cell adhesion and
downregulation can affect other proteins during EMT including cytokeratins,
desmosomes, and cell polarity proteins. During EMT, expression of E-cadherin
“switches” to N-cadherin, allowing for a more fibroblast-like morphology and increased
cell motility [41]. This phenomenon can be triggered through cellular release of growth
factors, such as TGFβ, PDGF, EGF, and FGF2 [42]. Specifically, TGFβ initiates a
response through the binding of receptors with serine/threonine kinase activity, which
subsequently phosphorylates Smad2 and Smad3 [43]. Activated Smad2 and Smad3
form a complex with Smad4 which is then translocated into the nucleus to activate
transcription of target genes [44, 45]. These genes act as transcription factors which
are responsible for regulating the EMT process (Fig. 1.2) [46].
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Figure 1.2: TGFβ Induces Transient EMT within Hours of Treatment through
Phosphorylation of the TGFβ Receptor.
The binding of TGFβ ligand to TGFβ receptors results in phosphorylation of the receptor and
a cascade of signaling events. First, Smad2/3 is activated through phosphorylation and
forms a trimer with Smad4. This trimer then translocates to the nucleus to form a complex
with co-transcription factors. Lastly, the complex activates or represses target gene
transcription. Of these, the EMT markers Snail, Slug, Twist, and Zeb are all transcribed.
(Adapted from Debangshu and Datta, 2012). (Figure created by Trillitye Paullin).

TGFβ is secreted by several cell types, including macrophages, B cells, and
dendritic cells, and its activation can be regulated by the BMP1 protease family [47]. Its
signaling is implicated in driving several developmental pathways and controlling
cellular behavior [48]. As such, TGFβ plays dual roles of both anti- and protumorigenesis depending on the cancer stage. In early-stage tumors, increased TGFβ
expression levels are linked to favorable prognosis due to its ability to stimulate cell
cycle arrest [49, 50]. However, it has been shown to enhance motility, invasion, EMT,
8

and stemness in advanced stage tumors [51]. This phenomenon has been coined the
“TGFβ paradox” [52]. Similarly, TGFβ is vital to inhibiting cell proliferation in normal
ovarian epithelial cells, however 40% of ovarian carcinomas are shown to contain
mutated TGFβ which negates its cytostatic effects while preserving its ability to induce
EMT [53]. In serous epithelial ovarian cancer, the 3q26.2 chromosomal region
containing TGFβ co-repressors, ecotropic viral integration site-1 (EVI1) and SnoN/SKiL,
is frequently amplified [54, 55]. In our studies, TGFβ was utilized to induce EMT in
SKOV3 and HEY ovarian cancer cell lines.
Recently, scientists have focused on EMT processes that are activated under
pathological situations as well, including tumor progression and metastasis [46, 56, 57].
In tumor progression, EMT allows the cells to detach from one another, invade the
basement membrane, and migrate to other organs within the body [58]. Once the
mesenchymal-like cell has migrated into a new organ, it can undergo MET and begin to
form a secondary tumor [46]. In fact, many studies have shown a functional loss of Ecadherin as one of the most important steps in cancer progression [59, 60]. The most
common E-cadherin alterations found in tumors include exon skipping and out-of-frame
mutations and it is believed that the protein acts as a tumor suppressor for certain
cancer types [61]. In many carcinomas, EMT-inducing transcription factors, such as
Snail, Slug, Twist, and Zeb, appear to be induced or activated by signals stemming from
the tumor-associated stroma [62, 63]. Such signals include growth factors such as
TGFβ, EGF, PDGF, and HGF. Downstream, these transcription factors activate EMT
through a series of signaling networks involving proteins such as MAPK, PI3K, Akt,
Smads, ERK, and many others [64].
9

Monolayer versus Spheroid Cell Culture
HeLa was the first continuous human cancer cell line which was derived from a
woman’s cervical cancer and developed in 1952 [65]. Today, there are hundreds of
cells lines originating from every histological type of cancer. A majority of cell lines used
for experimental purposes are considered adherent or monolayer cultures because they
are anchorage-dependent and grow on a solid substrate. While monolayer cultures are
commonly used to study ovarian cancer and the EMT process, the spheroid culture
model has been shown to be more physiologically relevant due to its significant
similarity to in vivo solid tumors in regards to pH conditions, oxygen levels, extracellular
matrix interaction, cell to cell interaction, and glucose levels [66-68]. This is especially
the case when studying metastasis, angiogenesis, and drug sensitivity [69-71]. Using
spheroid cultures is particularly important for this study, as ovarian cancer patients often
present with ascites [72]. Ascites is the accumulation of fluid in the peritoneal cavity, in
which ovarian cancer cells, lymphocytes, and mesothelial cells can be found [73]. This
occurs when malignant cells detach from the primary tumor into the ascitic fluid. These
free-floating cancer cells have sphere-forming capability and have been shown to hinder
treatment due to their role in metastasis, progression, and resistance to chemotherapy
treatment [74-77].
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Biomedical science began utilizing spheroidal cell clusters as early as the 1940’s
as a means to study morphogenesis in embryonic and malignant cells [78-81].
Sutherland and associates later used this concept to determine therapy response in
multicellular tumor spheroids [82, 83]. Research using 3D spheroids has led to new
discoveries in the processes behind invasion, angiogenesis, metastasis, and cell cycle
kinetics. Due to the relevance of spheroid cell cultures to actual in vivo solid tumors
(Fig. 1.3), 3D culture should become a mandatory test system in therapeutic screening
[84].

Figure 1.3: Spheroid Cell Culturing Closely Mimics Patient Tumors In Vivo.
Compared to monolayer cell culturing, which does not allow for areas of hypoxia, diverse
cell proliferation rates, and varying nutrient and waste transport, tumor spheroids have been
shown to be more physiologically relevant to tumors analyzed in vivo [1], even though these
tumors are capable of developing into nearly any shape. Some spheroid culturing methods
also include tissue support matrices which mimic the ECM in vivo. This makes spheroids a
better experimental model than monolayer cells. (Adapted from Phung et al., 2011). (Figure
created by Trillitye Paullin).

A wide variety of techniques are used to form spheroids from monolayer cell
culture. The spinner flask culture was the first method described and is still commonly
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used. In this method, fluid turbulence promotes cellular aggregation by preventing
attachment to other surfaces [82]. Using the same basic concept, the rotary wall vessel
reactor mimics microgravity by suspending cells between rotating cylindrical walls [85].
While these two approaches produce large quantities of spheroids, they also required
special equipment and processing methods. Another technique consists of placing cells
in non-adherent plates, however this usually results in less consistent spheroid size
[86]. An alternative method involves a microfluidic device that is based on
hydrodynamic trapping of cells in controlled geometries [87]. More recently, the
hanging drop method, was established and provided more reliable spheroid size and
arrangement [88]. Many new models for spheroid generation have been developed and
patented based around these original techniques [89]. Today, three dimensional cell
culture methods are grouped into three basic categories: cells cultured as multicellular
aggregates, on plastic inserts containing a rich matrix such as a matrigel, or embedded
in tissue support matrices meant to closely mimic the tumor microenvironment [89]. For
its simplicity and reproducibility, we utilized the hanging drop method to study the effect
of 3D spheroid cell culturing compared to monolayer in ovarian cancer cells.
Cancer Stem Cells
It has been postulated that a tumor may only arise through a small subclass of
cells known as cancer stem cells (CSC) or tumor-initiating cells. CSC are characterized
as tumorigenic, self-renewing, and pluripotent, meaning that they are capable of
developing into a tumor comprised of heterogeneous cells. CSC are resistant to current
conventional therapy options, allowing for their survival throughout treatment and
leading to patient relapse after treatment is discontinued. Research has implicated
12

CSC targeting mechanisms, such as differentiation therapy, as a necessity to halt the
reestablishment of the tumor. This treatment would involve introducing inhibitory RNA,
thereby blocking pathways which maintain stemness and causing the cells to
differentiate.
Research supports the existence of stem cell populations in ovarian cancer
patients [90]. In vitro studies have shown that a higher population of cancer stem cells
can be located within anchorage-independent growing spheres and that the formation of
said spheres is associated with cell differentiation [91]. This is important for ovarian
cancer because the disease disseminates into both peritoneum adherent nodules
containing their own blood supply as well as non-adherent spheroids which can be
found within the peritoneal cavity. Additional evidence relating cancer stem cells to
ovarian cancer progression is its unique reaction to bevacizumab, an anti-angiogenic
therapy through VEGF blockage which is vital to the interaction of stem cells to the
vascular niche [92]. In Chapter Two, we show that pathways for cancer stemness are
enhanced upon 3D spheroid culturing methods in HEY ovarian cancer cells.
The Heat Shock Response
The heat shock response (HSR) was discovered accidentally by Ferruccio
Ritossa in the 1960s. At the time, Ritossa was studying puffing patterns observed in
Drosophila busckii salivary gland chromosomes. The salivary glands are of particular
interest due to the chromosomal puffing changes directly related to expression levels of
the growth hormone, ecdysone [93]. After one of his lab mates changed the incubator
temperature for the fruit fly, Ritossa witnessed a puffing pattern change, indicating new
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RNA synthesis [94]. The first journal that he submitted these findings to rejected
Ritossa’s manuscript outright, claiming that it lacked biological significance. Eventually,
his article would be published in Experientia in 1962 [95].
Initially, this discovery slowly sparked different experiments at the cytological
level. It was discovered that the chromosomal response to temperature could be
produced in minutes [96, 97] and was associated with newly synthesized RNA [95, 98].
In early research, it was discovered that this shift in chromosomal puffing patterns could
be induced by stressors not related to temperature, such as inhibition of hydrogen
transfer between NADH and Coenzyme Q10 [98] or by the increase of oxygen tension
[99]. Since then, several other stress mechanisms have been linked to the HSR, to
include oxygen-free radicals, aging, cancer, infection, and heavy metals [100]. Further
studies in different Drosophila species and tissue types led scientists to believe that this
response was not limited to Drosophila busckii salivary gland chromosomes [97, 101,
102]. In fact, the HSR has been shown to be a highly conserved, universal response
which is found in every organism and nearly every cell and tissue type [103, 104].
Mechanics of the Heat Shock Response
The HSR is regulated by the phosphoprotein heat shock factor 1 (HSF1) is
located on chromosome 8 and exists naturally as a monomer bound to heat shock
protein 90 (HSP90). HSF1 and HSP90 dissociate upon stress, then homotrimerization
of HSF1 allows it to bind to heat shock elements (HSEs) in the promoter regions of heat
shock protein genes and stimulate transcription (Fig. 1.4) [105, 106]. HSF1 trimer
binding to adjacent HSE sites is highly cooperative [107]. Posttranslational
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modifications such as phosphorylation, deacetylation, and sumoylation are responsible
for controlling HSF1 activation [108]. HSF1 can be acetylated by p300, causing it to
attenuate off DNA, and can be deacetylated by the NAD+ dependent regulator SIRT1
[100]. Deletion of HSF1 in mammalian cells abolishes stress-induced HSPs expression,
however it does not change their normal basal expression [109].
HSEs are denoted by a five base pair sequence of nGAAn, where n is any
nucleotide, ordered in alternating orientation [110, 111]. The number of units within a
HSE usually ranges from three to five, producing a sequence such as

Figure 1.4: The Heat Shock Response through Activation of HSF1.
HSF1 is a phosphoprotein which exists as a monomer bound to Hsp90 under normal
conditions. Upon stress HSF1 binds to HSEs of HSPs and promotes transcription. HSF1
is later attenuated off of the HSEs through negative feedback from Hsp70 and Hsp90 as
well as acetylation. HSF1 is deacetylated by SIRT1, a NAD+ dependent protein
deacetylase. (Adapted from Akerfelt et al., 2010). (Figure created by Trillitye Paullin).
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TTCnnGAAnnTTC which is found approximately 1.5 helical turns upstream of the TATA
box [112]. This sequence is bound by each of the three HSF1 trimer’s DNA binding
sites within seconds of stress exposure [113-115]. Upon heat shock, HSE chromatin
regions become refractory to digestion, indicating protein binding [103].
Other Heat Shock Factors
The transcription factor HSF was originially discovered in 1984 through studying
DNA-protein interactions in Drosophila melanogaster cells [116, 117]. While
invertebrates only contained a single HSF, further research revealed expression of
multiple HSFs in plants and vertebrates [118, 119]. The HSFs expressed in mammals,
HSF1, HSF2, HSF3, and HSF4, HSF5, HSFX1, and HSFY1 exhibit both distinct and
corresponding functions. HSF1, found in mammals, is the ortholog to the single HSF in
S. cerevisiae, C. elegans, and D. melanogaster [120, 121]. The protein is vital to
development and Hsf1-/- mice exhibit female infertility, growth retardation, elimination of
the classical HSR, and prenatal lethality [109].
HSF2
In 1991, it was discovered that there were at least two separate HSF-related
genes in humans, coined HSF1 and HSF2 [122, 123]. These two sequences have 40%
idenity at the amino acid level, with the highest conservation found within the DNA
binding domain and heptad repeats. However, unlike HSF1, HSF2 in not activated by
celluar stress but instead by distinct signaling mechanisms related to the ubiquitinproteasome pathway [124]. Hemin, an iron containing protoporphyrin, induces
erythroid differentiation in K562 cells and activates HSF2 [125]. Through studies in
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mouse embryogenesis and spermatogensis, HSF2 has been found to be vital for
development and differentiation [126, 127]. Interestingly, while HSF2 deficiency is not
embryonically lethal, Hsf2-/- mice present with brain abnormalities, and meitotic and
gametogenesis defects in both males and females [128]. Recent research has shown
that HSF2 is decreased in a wide range of cancer tumor types, including ovarian serous
papillary eithelial cancer [129]. Furthermore, HSF2 suppresses prostate cancer tumor
invasion and low expression levels have been linked to poor prostate cancer patient
survival [129].
HSF3
Shortly after the discovery of HSF2, HSF3 was isolated and characterized from
avian cells in 1993 [130]. The sequence for HSF3 is approximately 40% related to both
HSF1 and HSF2, mainly found within the DNA binding domain and heptad repeats.
Sequencing of the syntenic regions for HSF3 between chicken, mouse, and human
revealed the mouse HSF3 gene, but only a human HSF3 psuedogene [131]. In avian
cells, HSF1 and HSF3 are coactivated by stressors and are both required for induction
of the HSR [132]. In fact, HSF3-null chicken B-lymphocyte cells significantly reduced
HSP70 inducible expression and halted expression of HSP40, HSP90α, HSP90β, and
HSP110 [133]. Independent of HS, HSF3 can be activated by the Myb oncogene via
direct protein-protein interaction [134].
HSF4
Through screening of human and mouse cDNA libraries with a chicken HSF3
cDNA probe, HSF4 was isolated and characterized [135]. HSF4 is highly expressed in
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the lens as a trimer due to its lack of a trimerization inhibitory domain, HR-C [135].
Deficiency in this gene causes cataracts in mice at early postnatal days [136]. HSF4
has been found to regulate nontraditional heat shock genes in murine lens cells
independently of the HSR. Among the genes associated with HSF4 binding regions,
approximately a third were induced upon HS [137]. In half of these genes, HSF4 was
required as a chromatin remodeler to facilitate the binding of HSF1 to the promoter
region [137].
HSF5, HSFY, and HSFX
HSF5 was discovered in 2001 as a potential HSF family member with a
conserved region of the DNA binding domain, however it has yet to be fully
characterized [138]. The HSFY gene is located within one of the three candidate
regions for azoospermic factor (AZF) of the Y chromosome. Three HSFY transcripts
were found to be differentially expressed in different tissue types, with transcripts 2 and
3 being testis-specific [139]. While the first transcript shares portion of the DNA binding
domain with other HSF family members, the other two transcripts lack this conservation
[139]. The expression of HSFY within the testis is highly dependent on its
spermatogenic stage [140]. Reduced expression of HSFY within the testis may be
associated with altered differentiation of spermatogenic cells in testes with deteriorated
spermatogenesis [141]. There is little information about HSFX as it has yet to be fully
characterized.
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HSF1 Functional Domains
HSF1 is made up of several highly characterized domains. The DNA binding
domain (DBD) is located on the amino-terminal region of the protein, and forms a
globular structure with a flexible wing section [142, 143]. This wing allows for a proteinprotein interface between the HSF1 monomers in order to promote the trimer binding to
HSEs in the promoter regions of HSPs. This binding is highly cooperative between the
subunits of the HSF1 trimer and from trimer to trimer, increasing the chances of a
second trimer binding to an adjacent HSE by over 2000-fold [144].
Just after the DBD lies an oligomerization domain composed of hydrophobic
heptad repeats (HR-A and HR-B) which are responsible for mediating HSF1
trimerization. This domain forms a coiled-coil, which is typical of a region containing
several Leucine zippers. However, while most Leucine zippers facilitate the assembly
of homodimers, the HSF1 heptad repeats form a triple-stranded configuration [119]. A
third heptad repeat domain (HR-C) is located more closely to the carboxyl-terminus and
is responsible for suppression of spontaneous HSF1 trimerization by folding back to
interact with the HR-A and HR-B domains [119, 145].
Located between HR-A/B and HR-C, amino acids 221-310, is the regulatory
domain (RD) which contains several serine residues that are phosphorylated upon
stress. This domain is responsible for inhibition of the transactivation domains which
make up the carboxy-terminal region of HSF1 [146]. The transactivation domains (AD-1
and AD-2) contain hydrophobic and acidic residues allowing the proteins to provide a
prompt and sustained response to stress [146, 147]. AD-1 is made up of amino acids

19

371-430, is negatively charged, and forms an α-helix, while AD-2 is made up of the last
100 amino acids in the protein, is negatively charged, and is rich in proline and glycine
[146, 148].
HSF1 Post-Translational Modification
HSF1 may undergo several different post-translational modifications which
dictate the proteins overall function within a cell at any given time (Fig. 1.5). Activation
of HSF1 is dependent on phosphorylation and several kinases have been shown to
activate HSF1. Such kinases include casein kinase 2 (CK2) phosphorylation of Thr142
[149], calcium/calmodulin-dependent protein kinase II (CaMKII) phosphorylation of
Ser230 [150], protein kinase A (PKA) phosphorylation of Ser320 [151], p38 mitogenactivated protein kinase (MAPK) phosphorylation of S326 [152], and polo-like kinase 1
(PLK1) phosphorylation of Ser419 [153]. Some HSF1 phosphorylation events, such as
Ser121, Ser303, Ser307, and Ser363, have a negative impact on transcriptional activity
[154, 155]. In addition to the sites described in Fig. 1.5, further phosphorylation sites
have been located on serine residues 97, 230, 314, 319, and 363, however only S326
phosphorylation was shown to significantly activate HSF1 upon heat shock [3].
After HSF1 has been hyperphosphorylated, it undergoes sumoylation at lysine
298 by SUMO-1. Neighboring consensus sequences for phosphorylation and
sumoylation together make up HSF1s phosphorylation-dependent sumolyation motif
(PDSM). Phosphorylation-mediated sumoylation of this domain is stress sensitive and
allows for the RD to restrict HSF1 activity. HSF1 sumoylation is persistent in cells
exposed to mild heat stress while it is more transient in cells which experience a severe
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heat stress [156].
HSF1 is subject to stress inducible acetylation which plays a role in the
attenuation of HSF1 activity. The domains most affected by acetylation are responsible
for protein subcellular location, oligomerization, and DNA recognition. Acetylation of
this protein may be increased by sirtuin inhibition and likewise decreased by
overexpression of sirtuin 1 (SIRT1), indicating that HSF1 is deacetylated by SIRT1
[100]. In fact, acetylation of K80 within the DBD deminishes the HSR by reducing DNA
binding activity. HSF1 deacetylation by SIRT1 was shown to promote the HSR by

Figure 1.5: Well-Described HSF1 Post-Translational Modification Sites.
Acetylation of K80 is responsible for HSF1s loss of DNA affinity. S121, S230, S298, S303,
S307, S320, S326, S419, and S444 are shown through mass spectrometry to be
phosphorylated upon heat shock treatment [3]. Phosphorylation of T142 is also responsible for
heat-induced transcriptional activity. Lastly, sumoylation at K298 by SUMO-1 inhibits HSF1
activity. (Adapted from Neef et al., 2011). (Figure created by Trillitye Paullin)

maintaining HSF1 in its DNA binding state [100]. This regulation of HSF1 via the
longevity factor SIRT1 may indicate why a reduction of the HSR is seen with aging.
Additional uncharacterized acetylation sites exist on lysine residues 116, 118, 126, 148,
157, 208, 224, 298, and 524 [100, 157].
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Heat Shock Proteins
Once HSF1 is bound to HSEs, it promotes transcription of heat shock protein
(HSP) genes, which are among the most highly conserved genes in existence. While
their transcription is induced by a stressor such as heat, they are also essential for
normal cellular functions at basal temperatures. HSPs are also responsible for reducing
the accumulation of damaged and misfolded proteins commonly found in aging cells. A
discrepancy in protein homeostasis is a hallmark of both normal aging and age-related
neurodegenerative diseases [158-161]. Molecular chaperones, such as HSPs, prevent
toxic protein aggregation by binding to non-native polypeptides and correctly folding
such proteins or by degrading them through the ubiquitin-proteasome system [162].
There are six major classifications of HSPs based on their molecular mass: small
HSP/HSPB, HSP40/DNAJ, HSP60/HSPD, HSP70/HSPA, HSP90/HSPC, and
HSP110/HSPH.
HSP27/HSPB
One such sHSP is heat shock protein 27 (HSP27), also referred to as HSPB1.
HSP27 contains a highly conserved α-crystallin domain, which is required for
oligomerization, within its 205 amino acid protein complex. As a protein chaperone,
HSP27 has been implicated in several cellular processes, to include growth,
differentiation, survival, and tumorigenesis [163]. HSP27s serine residue
phosphorylation can determine its biological function. Non-phosphorylated HSP27 acts
as an actin capping protein on the plus end of actin filaments, thereby inhibiting actin
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polymerization while phosphorylated HSP27 promotes polymerization [164]. HSP27
expression and HSP27 overexpression increased overall tumor size when colon
adenocarcinoma cells were injected into syngeneic rats [165]. Phosphorylation
inhibition of HSP27 causes reduced tumor cell migration and invasion in breast cancer
cells [166] and phosphorylation of Ser78 on HSP27 correlates with Her2/neu expression
[167].
HSP40/DNAJ
HSP40, or DNAJ, contains a J domain made up of 70 amino acid residues which
are responsible for binding the HSP70 nucleotide-binding domain (NBD) and stimulating
its ATPase activity through hydrolysis [168]. Known as co-chaperones, several
members of the HSP40 family have been characterized as binding a diverse array of
client proteins to be manipulated by HSP70. Through a multi-step process, hydrolysis
of ATP to ADP causes a conformation change in the HSP70 substrate-binding domain
(SBD), increasing HSP70 affinity for its aggregated target [169, 170]. After ADP is
replaced for ATP via nucleotide exchange factors (NEFs), the polypeptide is released
and can fold into its native conformation [171]. If the polypeptide remains misfolded, it
can either reenter the cycle for refolding or be targeted for degradation by the ubiquitinproteasome system [172].
HSP70/HSPA
HSP70 is one of the most highly induced proteins in response to cellular stress
[173]. HSP70 is present in the cytosol and in membrane-bound organelles and has a
number of client proteins. Misfolded client proteins are escorted by HSP40 to HSP70s’
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substrate-binding domain as described above. Its chaperone function for a wide range
of client proteins leads to HSP70s key influence on apoptosis [174], immunomodulation
[175], and tumorigenicity [176]. HSP70 knockdown has been shown to enhance cancer
cell death over normal cells because its down-regulation is cytotoxic to transformed
cells [177].
HSP90/HSPC
HSP90 plays a role in cellular homeostasis by providing stability and correctly
folding client proteins which have been denatured upon stress [112]. This chaperone
exists as an ATPase which recruits the assistance of co-chaperones to refold denatured
proteins [178]. Over 20 HSP90 co-chaperones have been discovered which work to
inhibit or activate HSP90 by regulating its ATPase activity or recruiting client proteins
[179, 180]. Identified client proteins are implicated in several physiological events, to
include signal transduction [181], tumor progression [182], cell cycle machinery [183],
apoptosis [184], telomere elongation [185], and cell invasion and metastasis [186]. Due
to its role in several oncogenic pathways, inhibition of HSP90 is being studied for its
potential anti-tumor affects [187, 188].
HSR Negative Feedback Mechanism
The HSR is thought to be regulated by a negative feedback loop mechanism
where HSF1 is kept inactive by the presence of excess HSPs [189]. Upon stress, HSPs
bind to client misfolded proteins and release HSF1 from chaperone complexes, allowing
for HSF1 trimerization and induction of the HSR. Once HSP expression has been
saturated, they will bind and inhibit HSF1 once more. This was shown through the
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activation of HSF1 by injection of non-native denatured proteins into Xenopus oocytes
[190].
HSF1 Target Genes
Target genes of HSF1 are implicated in a wide range of cellular functions
including cell division, development, insulin signaling, energy production, cytoskeletal
organization, and vesicular transport. The most investigated HSF1 target genes are
HSPs, as discussed above, which may serve as molecular chaperones to refold and
disaggregate damaged polypeptides. HSF1 activation of these genes is vital to cell
survival upon a number of stressors.
In addition to molecular chaperones, HSF1 is associated with several genes
implicated in other physiological responses. Through suppression of the NFKB
pathway, HSF1 binds directly to the nuclear factor of interleukin 6 (NF-IL6) and
represses transcription of IL-1 beta gene, which is an essential mediator of the
inflammatory response [191]. HSF1 has been shown to regulate expression of several
other non-HSP genes including heme oxygenase 1 (HO-1) [192], BCL2-associated
athanogene 3 (BAG3) [193], clusterin (CLU) [194], thrombomodulin (THBD) [195], and
plasminogen activator inhibitor-1 (PAI-1) [196].
HSF1 plays a critical role in oncogenesis which has been shown to be
transcriptionally unique from that of the classical heat shock response. Utilizing ChIPSeq analysis, it was determined that HSF1 strongly binds to several genes in cancer
cells which are not bound upon heat shock to include chaperone containing TCP1
subunit 6A (CCT6A), CDC28 protein kinase regulatory subunit 2 (CKS2), CDC protein
25

kinase regulatory subunit 1B (CKS1B), eukaryotic translation initiation factor 4A2
(EIF4A2), lymphocyte antigen 6 complex locus K (LY6K), RNA binding motif protein 23
(RBM23), and suppression of tumorigenicity 13 (ST13) [197]. Conversely, heat shock
protein family A (HSPA6/HSP70) and DnaJ heat shock family member C7
(DNAJC7/HSP40) genes were strongly bound by HSF1 upon heat shock but not in
cancer cells [197]. While the exact mechanism for HSF1’s district cancer role is not well
defined, scientists have postulated that cancer activated pathways, such as
EGFR/HER2 [198] and RAS/MAPK [199], may be implicated due to their ability to alter
HSF1 activity [197]. Further analysis of this specialized transcription pathway could
lead to new therapeutic targets in cancer treatment.
HSR and Aging
Several studies have implicated the HSR and HSPs in aging. Throughout the
aging process, cellular death and degeneration occurs within vital organs. This
degeneration causes an accumulation of damaged and dysfunctional proteins.
However, an increase of misfolded proteins within the cell is also coupled with a
diminishing of the HSR with age. Age-dependent decrease in the HSR can be found in
the liver, neuronal tissues, and skeletal and cardiac muscle [200-202]. Specifically in
neuronal tissues, this results in the formation of inclusion bodies, or aggregated
proteins. Inclusion bodies have been linked to several neurodegenerative disorders, to
include Alzheimer’s and Parkinson’s disease. Alzheimer’s disease has been associated
with amyloid-β peptide and tau aggregation while Parkinson’s stems from α-synuclein
inclusions. These connections implicate an age-dependent loss of protein quality
control as a potential cause. In fact, downregulation of HSF1 results in a shortened
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lifespan in C. elegans while overexpression lengthens it [203]. Additionally, shortened
lifespan was found in hsf1-/- mice which were inoculated with prions compared to wildtype mice [204].
Several studies have been conducted which focus on exercise-induced stress
response in skeletal muscles. In young organisms, non-damaging exercise results in a
significant increase in HSPs, while this is not the case for old individuals [205].
Interestingly, DNA binding activity of HSF1 is not reduced in old organisms, suggesting
that failure to induce the HSR occurring during or post-transcription [206].
HSR and Cancer
One of the basic hallmarks of cancer is that it must evade apoptosis in order to
continue cell proliferation and create a tumor. Commonly, this is accomplished through
the mutation or overexpression of one or more oncogenes or tumor suppressors.
Recent studies have shown that many cancer types may utilize HSF1’s potential
chaperone function to stabilize such oncogenes within the cell, thereby allowing the
cancer to progress [207]. Additionally, increased HSPs in tumor cells as compared to
normal cells provide a cytoprotective response in advanced cancers with acidotic,
hypoxic, and nutrient deprived microenvironments [208]. Likewise, HSP70
overexpression can cause reversible oncogenic transformation [209]. HSP70 may
increase drug resistance in some cancer cells due to its ability to inhibit apoptosis both
upstream and downstream of the mitochondria [210].
High HSP70 and HSF1 levels promote cell survival, migration, invasion, and
angiogenesis [108, 211-214]. Increased expression of HSF1 has been shown in
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prostate, breast, colon, bladder, and lung cancer [197, 215-217]. This influx in HSF1
and HSP70 levels has been connected to cancer metastasis, poor patient outcome, and
chemotherapy and radiotherapy resistance. Interestingly, this effect can be seen in
cancers derived from multiple oncogenes, including p53, RAS, NF1, and PDGF [207,
218-220]. HSF1 may also be used as a biomarker for poor patient prognosis and highly
metastatic tumors in these cancer types [197, 221].
In mice, HSF1 is recruited to enhance cancer cell survival, causing tumor size to
be greatly reduced in HSF1 knockout mice compared to wild type [207]. HSF1
knockdown in breast cancer cells inhibits spheroid formation, decreases cancer stem
cell marker expression, and increased sensitivity to paclitaxel chemotherapy treatment
[222]. Furthermore, HSF1 knockdown MEFs exhibited a significant suppression of
focus formation induced by PDGF-B [207]. In our studies, Chapter Three shows that
knockdown of HSF1 also reduced spheroid and focus formation in SKOV3 and HEY
ovarian cancer cells. Through microarray analysis, spheroid formation resulted in
differentially expressed genes involved in cancer stemness and tumorigenesis as seen
in Chapter Two.
HSF1’s ability to promote transcription of chaperones utilized for cancer
progression makes it and subsequent chaperones strong potential targets for cancer
therapy. New research has revealed that HSF1 expression is significantly higher in
malignant ovarian cancer tumors than in benign tumors [223], however further studies
have yet to be conducted showing its full effects within this deadly cancer. As shown in
Chapter Three, our studies show that HSF1 plays a vital role in ovarian cancer
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progression and that HSF1 knockdown reduces migration, invasion, and EMT in SKOV3
and HEY cell lines.
Specific Aims
The objective of this study is to investigate the difference between monolayer
and spheroid culturing and determine what role HSF1 plays in ovarian cancer
progression. We hypothesize that ovarian cancer monolayer cells will significantly
differ in gene expression profile from that of spheroidal cells, that HSF1
knockdown will inhibit ovarian cancer progression in both monolayer and
spheroid model cells, that the effects of this knockdown will be more fully
revealed in 3D culture, and that spheroids will prove more susceptible to the
chemotherapy agents paclitaxel and cisplatin upon HSF1 knockdown or
treatment with small molecule modulators of HSF1 and HSP90. The following
specific aims are intended to assess this hypothesis.
Specific Aim 1: Investigate the differences between monolayer and spheroid cell
culturing in ovarian cancer (Chapter 2).
1.1: Determine gene expression profile changes in 3D spheroids versus 2D
monolayers.
1.2: Validate microarray data through quantitative RT-PCR.
1.3: Evaluate pathways significantly affected by spheroid culturing.
Specific Aim 2: Determine HSF1’s role in ovarian cancer proliferation and progression
(Chapter 3).
2.1: Evaluate effects of HSF1 knockdown on ovarian cancer cell proliferation.
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2.2: Test the colony formation ability, and the migration and invasion efficiency of
ovarian cancer cells upon HSF1 knockdown.
2.3: Assess the consequence of HSF1 knockdown on EMT in 2D and 3D ovarian
cell culture.
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CHAPTER TWO: SPHEROID GROWTH IN OVARIAN CANCER ALTERS
TRANSCRIPTOME RESPONSES FOR STRESS PATHWAYS
AND EPIGENETIC RESPONSES
Authored by Trillitye Paullin, Chase Powell, Christopher Menzie, Robert Hill, Feng
Cheng, Christopher J. Martyniuk, and Sandy D. Westerheide
Submitted to PLoS ONE. October 2016.
Experiments were designed, performed, and analyzed by T. Paullin or performed under
the direction of T. Paullin. C. Menzie and T. Paullin performed qPCR analysis for Figure
2.4. Expression analysis and subsequent figures were created by C. Martyniuk and F.
Cheng. Manuscript was written by T. Paullin and S. Westerheide.
Introduction
Despite recent improvements in surgery and chemotherapy, ovarian cancer is
still the leading cause of death from gynecological malignancy [224]. Due to poor
detection methods and a lack of symptoms, most patients are diagnosed at advanced
stages, when the tumor has metastasized and spread [225]. Studies suggest that in
order for metastasis to occur, the cancer cells must undergo phenotypic changes
modulated by the epithelial-mesenchymal transition (EMT) [58].
EMT is a distinct process whereby epithelial cells undergo changes in favor of
mesenchymal properties [35]. This process is most commonly observed during
developmental stages when epithelial cells must migrate and dedifferentiate, such as in
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the formation of the mesoderm during gastrulation [36]. A well-defined inducer of EMT
is transforming growth factor-β (TGFβ) [226, 227]. The addition of TGFβ to epithelial
cells induces transient EMT within hours of treatment through activation of the Smad
pathway [228].
Although two dimensional (monolayer) tissue culture models are largely used to
study the EMT process, evidence suggests that three dimensional (spheroid) culturing
may be more physiologically relevant as it better emulates oxygen levels, pH conditions,
glucose levels, extracellular matrix strength, and overall morphology of in vivo solid
tumors [66-68, 229]. This is especially the case when focusing on metastasis, tissue
invasion, angiogenesis, and drug sensitivity [69-71].
At least a third of ovarian cancer patients present with ascites [72]. Ascites is the
accumulation of fluid in the peritoneal cavity which may contain ovarian cancer cells,
lymphocytes, and mesothelial cells in the form of single cells and aggregates [73].
Further studies revealed that ascites spheroids may cause secondary tumors due to
their ability to adhere to extracellular matrix proteins via interaction between multiple
integrins and their ligands [230, 231]. Here, we conducted a comprehensive gene
expression analysis for the process of culturing HEY ovarian cancer cells in 3D vs. 2D
cultures during the TGFβ-induced EMT process. Using subnetwork enrichment
analysis, we identified stress pathways, DNA integrity pathways, and epigenetic
processes as those most affected by 3D vs. 2D growth.

32

Materials and Methods
Cell Culture and Treatments
The HEY human ovarian cancer cell line was authenticated by short tandem
repeat (STR) DNA profiling (Genetica, Inc.) and was compared to ATCC and previously
published profiles [232]. Cells were cultured in a humidified incubator containing 5%
CO2 at 37oC in RPMI with 10% fetal bovine serum and 1% Pen-Strep-Glutamine.
Spheroid formation was accomplished through the hanging drop method. Briefly,
trypsinized HEY cells were resuspended at 1 x 106 cells/mL in supplemented RPMI.
Multiple 25 µl droplets of the cell solution were then placed onto plate lids, inverted, and
incubated for 72 hours to allow cells to aggregate into spheroids. To induce EMT, a
final concentration of 10 ng/µl TGFβ was added to cells and incubated for 72 hours as
monolayer cell culture or hanging drops during the creation of spheroids. Following
incubation, monolayer cells and spheroids were photographed using an Evos® FL Cell
Imaging microscope (ThermoFisher Scientific) and then collected in 1X PBS.
Quantitative RT-PCR
RNA was extracted from harvested cells using the RNeasy Mini Kit (Qiagen).
RNA samples were then reversed transcribed with a High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems) per the manufacturer’s instructions. Subsequent
samples were then diluted to 50 ng/ µL and used as a template for quantitative PCR
(qPCR). qPCR was accomplished with a Step One Plus Real-time PCR system
(Applied Biosystems) and SYBR® Green Supermix with ROX (BioRad) according to the
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manufacturer’s protocol. Relative mRNA levels were quantified for ahnak2, akr1c1,
ccdc80, hspa1a, hsph1, prss35, rgs2, and rrad using gene-specific primers (Table 2.1).
Affymetrix GeneAtlas Platform and 3’IVT Compatible U219 Probe Arrays
The oligonucleotide probe arrays used were the Affymetrix HG-U219 human
array strips. These arrays consist of more than 530,000 probes detecting over 36,000
transcripts and variants-representing more than 20,000 genes.
Sample Processing and Validation
HEY Human ovarian carcinoma cells treated with TGF-β were cultured on a 2dimensional substrate or 3-dimensional substrate as described above. Replicates of 4
separate experiments were performed on 4 different culturing days, cells isolated and
stored in RNAlater Soln (Ambion) for no more than 7 days. Up to 100 µg of total RNA
was isolated from all 8 samples using Qiagen’s RNeasy Mini Kit according to the
manufacturer’s instructions. RNA integrity was verified with 1 µl of total RNA on RNA
6000 nanochips (Agilent) using The Agilent 2100 Bioanalyzer. All results for all 8
samples reported RNA Integrity Numbers (RIN) > 9. 100 ng of polyadenylated RNA
was converted to cDNA and then amplified and labeled with biotin using Affymetrix
3’IVT Expression System according to the manufacturer’s instructions. Hybridization
with the biotin-labeled RNA, staining, and scanning of the chips followed the proscribed
procedure outlined in the Affymetrix technical manual and has been previously
described.
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Data Analysis
Scanned output files were visually inspected for hybridization artifacts and then
annotated and normalized using Affymetrix Expression Console v1.3.1. Additionally, all
QC metrics reported no outlier samples. Signal intensity was scaled to an average
intensity of 500 during comparison analysis. Annotated expression data were assigned
an ANOVA P value for the likelihood that any perceived difference was due to chance.
The P values for all probe sets were exported to a text file and all pairwise comparisons
of Bi-weight average signals were then aligned in MS Excel. For the comprehensive
analysis, P < 0.05 was identified as having a linear change (increased or decreased) for
the comparison. This analysis reported ~3,329 genes that showed differential regulation
greater or less than 2-fold. To increase stringency, only genes whose fold-change was
greater than or less than four (p < 0.05) were considered to be differentially expressed,
reducing the pool to 493 candidate genes.
Data were analyzed using different visualization techniques that included
hierarchical clustering, principle component analysis (PCA), and Volcano plots. All
analyses were conducted in JMP Genomics v7.0. Transcripts that showed p<0.01 were
used in the two-way clustering using the Fast ward algorithm after each row was
centered to a mean of zero (0) and variance scaled to one. Results from hierarchical
cluster analyses were visualized using heat map dendrograms, and biological replicates
are partitioned into groups based on similarity (i.e., individuals clustered together are
most similar). PCA used spatially weighted averages and were conducted on
normalized expression values, the same dataset used in the cluster analysis. Volcano
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plots were generated in JMP Genomics 7.0 following an ANOVA to identify differentially
expressed transcripts.
Pathway Studio Analysis
Pathway Studio 9.0 (Elsevier) and ResNet 10.0 were used for sub-network
enrichment analysis (SNEA) of cell processes [233] . The option of “best p value,
highest magnitude fold change” in Pathway Studio was used for duplicated probes.
Transcripts were successfully mapped using GeneBank ID. SNEA was performed to
identify gene networks that were significantly different. A Kolmogorov–Smirnov test with
1000 permutations was conducted to determine whether certain networks were
preferentially regulated compared to the background reference probability distribution.
Networks are constructed based on common regulators of expression and regulators of
specific cell processes. The enrichment P-value for a gene seed was set at P < 0.05.
Additional details on the use of SNEA can be found in Langlois and Martyniuk [234] .
Results and Discussion
HEY Cells Treated with TGF have Distinct Gene Expression Profiles when grown as
3D Spheroids vs. 2D Monolayers
To examine whether growth of HEY ovarian cancer cells as 3D spheroids vs. 2D
monolayers could influence gene expression, we performed microarray analysis on
biological quadruplets with cells grown under each condition. To create spheroids, the
hanging drop method [235] was used as outlined (Fig. 2.1). We find that HEY cells
treated with TGF have distinct gene expression profiles, depending on whether they
are cultured under 2D vs. 3D conditions (Fig. 2.2). Hierarchical clustering reveals that
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each of the two groups form into distinct clades based on gene expression (Fig. 2.2A).
Additionally, principle component analysis shows that biological quadruplicates for HEY
2D and HEY 3D samples are more similar to themselves than to each other (Fig. 2.2B).
Volcano plot analysis shows that there are numerous genes between the two groups
that have a high fold change and that are also statistically significant (Fig. 2.3).
RT-qPCR was performed on eight different genes which were found to be up or
downregulated by varying degrees upon 3D culturing to validate our microarray analysis
(Fig. 2.4). The eight genes we chose to validate include two highly upregulated genes,
the serine protease PRSS35 and the aldo-keto reductase AKR1C1, as well as the
highly downregulated E-cadherin regulator CCDC80. Additionally, we chose some
genes that were more moderately regulated, including the chaperones HSP110 and
HSP70, the G-protein signaling inhibitor RGS2, the fibroblast growth factor secretion
regulator AHNAK2 and the apoptotic inducer RRAD. Our results show that similar
trends are observed via RT-qPCR for these genes as compared to our microarray
results. Overall, our data show that HEY ovarian cancer cells, treated with TGF to
induce EMT, show dramatic differences in gene expression profiles when grown as 3D
spheroids vs. standard 2D culture.
Transcripts Affected by 3D Culturing may Enhance the Tumorigenicity of HEY Cells
Growth as 3D spheroids leads to both the upregulation and downregulation of
gene expression (Table 2.2). The most highly upregulated gene under 3D growth
conditions in HEY cells is AKR1C1 (Aldo-Keto Reductase Family 1, Member C1), part of
a family of cytosolic NADP(H)-dependent oxidoreductases that is involved in
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detoxification of xenobiotics, steroids, and polycyclic aromatic hydrocarbons
[236]. Increased expression of AKR1C1 is associated with the development of cisplatin
resistance in human ovarian carcinoma cells [237]. Previous work shows that ovarian
cancer cells, grown in 3D, are more resistant to chemotherapy treatment [74]. It is
therefore plausible that the increased expression of AKR1C1 upon ovarian cancer cell
3D growth may promote chemotherapy resistance. PRSS35 (Protease, Serine 35),
another highly upregulated gene upon 3D growth, belongs to the trypsin class of serine
proteases. This protease is highly expressed in the mouse ovary [238]. Proteases play
an important role in proteolysis that is essential for tissue remodeling that occurs during
EMT by breaking down the extracellular matrix. While metalloproteases play the largest
role in this process, serine proteases also contribute [239]. We postulate that enhanced
expression of PRSS35 under 3D growth conditions may promote ovarian EMT through
the proteolytic digestion of cell attachments. A transcript that was highly downregulated
upon 3D growth is CCDC80 (Coiled-Coil Domain Containing 80). Interestingly,
CCDC80 null mice develop thyroid adenomas and ovarian carcinomas, and CCDC80
gene expression is decreased in human ovarian cancer samples as compared to
normal ovarian samples [240]. The mechanism for the tumor suppressor properties of
CCDC80 may be through its ability to induce E- cadherin expression [240]. E-cadherin
provides crucial cell-cell adhesion to hold epithelial cells tightly together, and enhanced
E-cadherin expression promotes the epithelial phenotype over the cancer-promoting
mesenchymal phenotype [241]. Collectively, we propose that regulation of these and
other genes upon 3D growth may enhance the tumorigenic properties of ovarian cancer
cells.
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Gene-Set Enrichment Analysis Reveals Novel Pathways that are enriched upon HEY
Cell Growth as 3D Spheroids
Gene set enrichment analysis suggested that pathways downregulated by more
than 15% include branched chain amino acid metabolism, folate biosynthesis, fatty acid
oxidation, and the mevalonate pathway, while pathways upregulated in the 3D cells
include those related to tumor necrosis factor receptor (TNFR) superfamily member 1A
and 6. These pathways were increased more than 20% with 3D growth in HEY cells,
and they have all been related to cancer growth. Branched chain amino acids, such as
leucine, positively regulate the mammalian-target-of-rapamycin (mTOR) pathway [242].
The mTOR pathway is involved in regulating cellular functions involved in growth and
proliferation, and upregulation of this pathway is commonly observed in human cancers
[243]. Folate plays a role in nucleotide synthesis and methylation, making it essential to
rapidly growing cancer cells [244]. Fatty acid oxidation is required for functional
angiogenesis and is utilized by cancer cells to overcome metabolic stress to proliferate
[245]. The mevalonate pathway is responsible for converting acetyl-coenzyme A into
isoprenoids, which are required for cholesterol and steroid synthesis [246]. LDLcholesterol accumulates in cancer tissues and is associated with migration, proliferation,
and loss of adhesion from the primary tumor which are vital steps in the epithelial to
mesenchymal transition [246]. Upregulation of TNFR family members allows signaling
via the NF-κB transcription factor, which can promote tumorigenesis through the
activation of the expression of genes involved in processes including cell proliferation,
migration and anti-apoptosis [247].
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Transcriptional Networks Involving Stress Pathways are Altered in HEY Cell Growth as
3D Spheroids
Unique sub-networks underlie the transition from 2D to 3D growth in HEY cells
(Table 2.3, for a complete list of enriched cell networks see Appendix B). We note that
a number of the identified sub-networks are related to the response to stress (Fig. 2.5,
for a complete list of gene networks related to stress Appendix C). The finding that
stress responses are activated upon 3D growth is not surprising, given that growth
under these conditions is likely to cause nutrient limitation and hypoxia, among other
cellular stresses.
Transcripts in the network that are related to the oxidative stress response
include Peroxiredoxin 2 (PRDX2) (Fold change = +2.2), Catalase (CAT) (+1.3),
Superoxide dismutase 1, soluble (SOD1) (+1.2), and Glutathione S-transferase omega
1 (GST01) (-1.3). In 1984, it was shown that transformation may result from the
exposure of reactive oxygen species to mouse fibroblasts [248]. It has since then been
hypothesized that the rise in cancer diagnosis for older individuals may be due to a
lifetime of DNA damage by reactive species accumulated endogenously and
exogenously [249]. Oxidative stress activates ERK/MEK and PI3K/AKT pathways and
impacts signaling proteins important in cancer such as Ras, Raf, p53, PKC, c-Myc, and
Nrf2 [250-252]. The changes detected in the oxidative stress pathway upon growth of
HEY cells in 3D may thus promote tumorigenic properties of the cells.
Also changed in 3D cells are transcripts that are associated with the heat shock
response. Some examples include heat shock protein 90kDa alpha (cytosolic), class A
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member 1 (HSP90AA1) (+1.16), heat shock 27kDa protein 1(HSPB1)(+1.20), and heat
shock transcription factor 1 (HSF1) (+1.28). Recent studies have suggested that many
cancer types utilize activation of heat shock factor 1 (HSF1), the master regulator of the
heat shock response, to stabilize oncogenes within the cell [207]. The heat shock
response is a highly conserved response to specific environmental stressors such as
heat shock, heavy metals, and oxidative stress [104]. HSF1 promotes the transcription
of heat shock protein genes, many of which encode molecular chaperones. Increased
chaperone expression provides a cytoprotective response in advanced cancers with
acidotic, hypoxic, and nutrient-deprived microenvironments [208]. Elevated levels of one
or more chaperones are commonly found in both solid cancer tumors and hematological
malignancies [253-257]. In fact, overexpression of HSP27, HSP70, or HSP90
correlates with poor prognosis and may contribute to drug resistance in some cancer
types [258-261]. Activation of the heat shock response in spheroids may promote cell
survival, in the face of multiple cellular stresses, through enhanced expression of HSF1
target genes, including molecular chaperones. Further analysis of this spheroid model
could offer valuable insight into how HSF1 and HSPs could be utilized as targets for
chemotherapy in ovarian cancer patients.
Other examples of stress-related genes that show a high magnitude of response
in terms of downregulation include the PIF1 5'-to-3' DNA helicase homolog (S.
cerevisiae) (-13.0), epidermal growth factor receptor (-4.6), far upstream element
(FUSE) binding protein (-4.4), and cysteine-rich, angiogenic inducer (-4.4). Increasing
transcripts in the network included nuclear factor of kappa light polypeptide gene
enhancer in B-cells inhibitor, alpha (+10.3), FBJ murine osteosarcoma viral oncogene
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homolog (+14.7), prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase
and cyclooxygenase) (+29.5), and interleukin 8 (+49.8). Many of these aforementioned
transcripts have been shown to play critical roles in the progression of cancer. For
example, PIF1 is a DNA-dependent adenosine triphosphate (ATP)-metabolizing
enzyme that is required for proper replication and repair during cell division. Studies
show that this protein inhibits S-phase progression and reduces proliferation rates of
RAS oncogene-transformed fibroblasts [262], and may therefore be a novel drug target
for cancer therapy. Here, the downregulation of PIF1 mRNA may lead to increased
proliferative activity during the transition from a non-cancerous cell to a cancerous cell.
Our network analysis also identifies DNA duplex unwinding (down regulated -1.49) and
S-M checkpoint (down-regulated -1.59) as processes significantly down-regulated in 3D
spheroids, processes which may be related to changes in PIF1 expression. In terms of
ovarian cancer, there are many studies implicating epidermal growth factor receptor
(EGFR) as a key regulator of cell differentiation Specifically, EGF-induced EMT
increases phosphorylation of Akt, ERK1/2, and S6 ribosomal protein, which alters
ovarian cancer cell proliferation and differentiation [263]. Additionally, elevated EGFR
expression in tumor stroma is linked to aggressive epithelial ovarian cancer in patients
and relates to Ki-67 expression in tumor cells [264]. In terms of up-regulated
transcripts, notable transcripts included FBJ murine osteosarcoma viral oncogene
homolog, a member of the Fos family of transcription factors. In cancer, this gene is a
proto-oncogene implicated in cell proliferation and transformation [265]. Lastly of
interest in the network was IL8, a gene that showed a dramatic increase in expression
of ~50-fold in 3D cells (Table 2.2). Polymorphisms in this gene have been shown to be
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associated with a significantly higher risk of ovarian cancer [266, 267]. Studies also
show that increases in IL8 is associated with increased tumor growth and metastases
[268].
Various responses related to DNA integrity were altered, including the response
to DNA damage, genetic instability, nucleotide excision repair, and the DNA damage
checkpoint pathway. The hypoxic environment created within spheroids may lead to
increased DNA damage. Spheroid culturing has shown to alter chromatin packaging
which in turn improves DNA repair through what is known as the “contact” effect [269].
DNA damage via metabolic products and by-products, such as ROS, may decrease
replication fidelity, resulting in increased mutagenesis. Mutations and chromosomal
abnormalities can increase the risk of cancer through the activation of oncogenes or the
inactivation of tumor suppressor genes. Complex DNA-damage response mechanisms
have evolved in order to isolate and repair these mutations. One such mechanism is
the nucleotide excision repair (NER) pathway. NER is able to eradicate a variety of
DNA lesions due to its ability to circumvent recognition of the lesion itself and focus on a
set of commonalities shared by many different lesions [40]. Our analysis showed a
significant enrichment of the NER pathway when cells are cultured as 3D spheroids.
Sub-Network Enrichment Analysis Identifies that Genes Involved in Epigenetic
Processes are enriched upon HEY Cell Growth as 3D Spheroids
Two epigenetic processes, DNA methylation and histone acetylation, are also
enriched upon 3D growth. A number of genes are both up- and downregulated related
to DNA methylation, and this process is affected by about 4-5% (Fig. 2.6). DNA
methylation changes are seen in several cancer types and have been linked to changes
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in gene expression in highly metastatic tumors [270]. The process of histone acetylation
is also significantly affected in both positive and negative fashions (Fig. 2.7).
Conclusion
Spheroid formation more closely mimics that of an in vivo tumor due to the cells
ability to form an extracellular matrix and cell adhesions. Here, using the HEY ovarian
cancer cell line, we show that 3D spheroid growth utilizing the hanging drop method
affects a number of cellular processes, including the multiple cellular stress pathways,
DNA integrity pathways, and epigenetic pathways. As these pathways all could affect
tumorigenesis and the response to chemotherapies, our studies suggest that using 3D
culture instead of 2D monolayers may be more informative in studying the properties of
ovarian cancer cell lines.
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Table 2.1: List of Primers used in Quantitative RT-qPCR.
Gene Name

Sequence

AHNAK2

F: 5' - GAAAATCCCAGAGCCCCACA - 3'
R: 5' - GTGCCCTCCTGAGTCCTAGA - 3'

AKR1C1

F: 5' - TGGCCATCCGAAGCAAGATT - 3'
R: 5' - GAGGATCATCTCCAGCTGCC - 3'

CCDC80

F: 5' - CACGCAGAGTCCCAAGAAGT - 3'
R: 5' - CAAAATTGCACGCCTGACCA - 3'

HSPA1A

F: 5' - GAGGGCCATGACGAAAGACA - 3'
R: 5' - TCGCTGATCTTGCCCTTGAG - 3'

HSPH1

F: 5' - AGGATCTCCCAAGCCTGGAT - 3'
R: 5' - TGGAGAAAGGAGCAGCATGG - 3'

PRSS35

F: 5' - GCTGAAGCGTGCTCACAAAA - 3'
R: 5' - GTCGGACACACTGCAAAACC - 3'

RGS2

F: 5' -TCTACTCCTGGGAAGCCCAA - 3'
R: 5' - GAGGACAGCTTTTGGGGTGA - 3'

RRAD

F: 5' - CCATGGGGGATGCCTATGTC - 3'
R: 5' - CGGCTGTTACGAGCTACGAT - 3'
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Figure 2.1: Establishment of 3D Mesenchymal Cell Populations from Confluent
Monolayers.
A) HEY cells grown in a monolayer are released and then suspended in drops of culture media
containing TGFβ (20,000 cells per drop) using the hanging drop method. After 72 hours, the
resulting 3D spheroids are then assayed. B) Image of HEY cells grown in monolayer culture.
C) Image of HEY cells grown as a 3D spheroid and treated with TGFβ.
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Figure 2.2: HEY Cells Treated with TGFβ have Distinct Gene Expression Profiles when
grown as 3D Spheroids vs. 2D Monolayers.
A) Hierarchical clustering of expression profiles. Clustering revealed that each of the two
groups form into distinct clades based on expression. B) Principle component analysis for
expression profiles. Variability in transcriptome response separates strongly along the first
PCA1. Red color is HEY 2D biological replicates and green color is HEY 3D biological
replicates. Biological replicates for HEY2D are more closely related in expression compared
to HEY 3D.
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Figure 2.3: Volcano Plot for Differentially Expressed Transcripts.
The Volcano plot shows the significantly expressed transcripts vs. fold change of the pairwise
comparison made between the two groups. Negative log10 p value on y axis indicates the
significance of each gene, and the fold change (log base 2) mean expression difference on x
axis. The dashed line is the significance threshold for selecting the differentially expressed
genes at FDR of 0.05.
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B.

Figure 2.4: Real Time PCR Analysis Validates Microarray Results.
A) Real time PCR results for select genes that are moderately to highly affected by 3D vs.
2D growth. Biological and technical triplicates were utilized. B) Microarray results are
plotted for the same genes.
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Table 2.2: Top 20 Genes with most Significant Fold Changes

Transcripts are organized as those down-regulated and up-regulated between the two groups. The
gene, as well as the role of the protein in the cell is provided in addition to the relative fold change and
p-value. For a complete list of gene expression changes see Table S2.
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Table 2.3: Top SNEA Pathways.

Only cell processes that showed >5% change in the pathway, as well a significant change at p>0.001
are shown. Provided are the total number of neighbors within a network, number of neighbors measured
on the microarray, the median fold change of the network, and the p-value. All cell processes
differentially expressed between cells are provided in Table S3. Major themes included those related
to cell cycle DNA damage and repair, and stress.
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Figure 2.5: Gene Networks Related to Stress.
These cell processes were significantly enriched following sub-network enrichment analysis
when comparing 3D vs. 2D growth. These processes were preferentially increased in the 3D
group. Red indicates the gene is upregulated and blue indicates the gene is downregulated.
All genes for pathways are listed in Supplemental Files.
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Figure 2.6: DNA Methylation.
DNA methylation was significantly enriched following sub-network enrichment analysis when
comparing 3D vs. 2D growth. DNA methylation was preferentially increased approximately
4% (197 genes measured, P = 0.006) in the 3D group at the level of the transcriptome based
on the sub-network enrichment analysis. Red indicates the gene is up-regulated and blue
indicates the gene is down-regulated. All genes for pathways are listed in Supplemental Files.
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Figure 2.7: Histone Acetylation.
Pathway for histone acetylation. A number of histone modifying enzymes were increased in
expression in the 3D group, and this may be reflective of chromatin remodeling during cancer
progression. Red indicates the gene or process is up-regulated and blue indicates the gene
or process is down-regulated. All genes for pathways are listed in Appendices.
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CHAPTER THREE: THE HEAT SHOCK TRANSCRIPTION FACTOR HSF1 INDUCES
OVARIAN CANCER EPITHELIAL-MESENCHYMAL TRANSITION IN A 3D
SPHEROID GROWTH MODEL
Authored by Chase Powell*, Trillitye Paullin*, Candice Aoisa, Christopher Menzie,
Ashley Ubaldini, and Sandy D. Westerheide *Co-first authors
Submitted to PLoS ONE. October 2016.
Experiments were designed, performed, and analyzed by C. Powell and T. Paullin or
performed under the direction of C. Powell and T. Paullin. Manuscript was written by T.
Paullin and S. Westerheide.
Introduction
Ovarian cancer is the number one gynecological malignancy cause of death
[271]. This is partially due to a lack of physical symptoms during early cancer stages as
well as shortcomings in screening techniques. In fact, a majority of newly diagnosed
ovarian cancer cases present with stage III and IV disease [272]. Recent advances in
surgery and chemotherapy treatment have led to improvement in short-term survival of
ovarian cancer patients, however long-term survival remains bleak [225]. Conventional
chemotherapy agents used to treat ovarian cancer include platinum and taxol-based
drugs. While these agents are largely effective upon initial treatment, the patient
commonly develops resistance to the drugs, yielding them inefficient should the patient
relapse [273]. In addition, agents such as cisplatin can be toxic to the patient’s organs,
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such as the kidneys and gastrointestinal tract, indicating a need for more efficient, as
well as safer, treatment options [274].
The heat shock response (HSR), driven by the heat shock transcription factor
HSF1, is a cytoprotective response to proteotoxic stressors, including heat shock, that
results in the induction of various genes including molecular chaperones essential for
recovery from cellular damage [275]. Chaperones function to guide protein folding and
protect cells against proteotoxic stress [276]. The HSR is regulated at the transcriptional
level by the heat shock transcription factor 1 (HSF1) [275].
Multiple lines of evidence suggest that HSF1 is important in promoting
tumorigenesis. For instance, studies in HSF1 null mice show they are refractory to
chemically-induced tumors, and HSF1 -/- mouse embryonic fibroblasts resist oncogeneinduced transformation [207]. In cancer, HSF1 controls many genes that may support
the transformed phenotype, including genes involved in cell-cycle regulation, signaling,
metabolism, adhesion and translation [197]. HSF1 is elevated in breast, colon, lung and
hepatocellular cancers, and activated or elevated HSF1 often couples with poor cancer
prognosis [197, 212].
The dissemination of primary tumors occurs through a multi-step process called
the epithelial-to-mesenchymal transition (EMT). EMT consists of detachment of primary
tumor cells, infiltration of local stroma, spread through cavities or vascular and lymphatic
vessels, and adhesion followed by colonization at distant sites [277]. Sweeping changes
are made in the cytoskeleton and extracellular matrix during EMT, and cells develop a
spindle-like morphology. TGFβ inhibits proliferation in normal tissues, but this effect is
lost in advanced cancer where it strongly promotes EMT [278]. The expression of a
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number of transcription factors are induced by TGFβ and support the EMT process,
including SNAI2/SLUG, SNAI1/SNAIL, TWIST1 and ZEB1 [277]. Once the
mesenchymal-like cell has migrated into a new organ, it can then undergo the reverse
mesenchymal-to-epithelial transition (MET) and begin to form a secondary tumor [46].
Here, we have established two ovarian cancer inducible HSF1 knockdown cell
lines to study the effect of HSF1 on ovarian cancer. We show that HSF1 knockdown
inhibits colony formation, wound healing, migration and the induction of FN1/fibronectin,
a protein important in the EMT process. We also show that the induction of EMT
markers by TGF is enhanced when cells are grown as 3D spheroid cultures vs. 2D
monolayer cultures. Upon 3D culturing, there is a marked effect of HSF1 on the
induction of transcription factors known to promote EMT. HSF1 knockdown also alters
spheroid morphology. Thus, we conclude that HSF1 plays a striking role in regulating
the EMT process under 3D growth conditions.
Materials and Methods
HSF1 Copy Number, Expression Determination, and Survival Analysis
Data comparing HSF1 copy number across multiple cancers with GISTIC
analysis was obtained from The Cancer Genome Atlas (TCGA) via the cBio portal [279,
280]. HSF1 expression levels across multiple cancers were assessed from TCGA RNA
seq V2 data via the cBio portal. Data for the comparison of ovarian cancer and normal
ovarian tissue were obtained from GEO and the TCGA. The datasets analyzed were:
GSE18520, consisting of 10 normal ovary and 53 ovarian cancer samples assayed on
Affymetrix HG-U133 Plus 2.0 GeneChips, and TCGA data, consisting of 8 normal ovary
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and 568 ovarian cancer samples assayed on Affymetrix HG-U133A GeneChips. Gene
intensity was compared by one-sided unpaired T-test.
Cell Culture and Treatments
HEY, SKOV3 and T80 cells were authenticated using short tandem repeat (STR)
DNA profiling (Genetica, Inc.) and comparing profiles to ATCC profiles and other
previously published profiles [232]. Cells were cultured in RPMI 1640 medium
supplemented with 10% fetal bovine serum (GIBCO) and 1% Pen-Strep-Glutamine
(CellGro) in a humidified incubator at 37oC with 5% CO2. Heat shock treatment was
performed by wrapping plates in parafilm and submerging them in a 42oC circulating
water bath for designated times. Cells were treated as indicated with 1 µg/ml
doxycycline (Sigma-Aldrich) and 5 ng/mL TGFβ1 (Thermo Fisher).
Lentiviral Creation and Infection for Stable, Inducible shRNA-Mediated HSF1
Knockdown
To allow for inducible knockdown of HSF1, we utilized the doxycycline-inducible
TRIPZ shRNAmir system (Thermo Scientific). Two shRNA sequences targeting HSF1
were obtained from the RNAi codex database [281]: CGCAGCTCCTTGAGAACATCAA
(shHSF1A) and CCCACAGAGATACACAGATATA (shHSF1B). These two sequences
were cloned into the pTRIPZ vector. For lentiviral packaging, a 2nd generation lentiviral
system was used with the pCGP packaging and pVSVG envelope plasmids (Addgene).
HEK293T cells, cultured in RPMI medium, were used as the packaging cell line.
Transfection was achieved using Polyfect Transfection Reagent (Qiagen) according to
the manufacturer’s protocol using a 1:1:1 ratio of lentiviral vectors. 24 hours posttransfection, medium with transfection reagent was removed and replaced with fresh
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RPMI. Medium containing viral stock from the HEK293T cells was harvested 48 hours
post-transfection. A 0.45 micron PVDF filter was used to filter viral stock and infection
of the HEY and SKOV3 cell lines was performed in a single round with the addition of 8
µg/mL of hexadimethrinebromide (Sigma-Aldrich). Selection of stable HEY and SKOV3
cells was achieved with 1 µg/ml and 0.5 µg/ml of puromycin (Thermo Fisher) for the
HEY and SKOV3 cell lines, respectively. Infection was verified via immunoblotting
analysis for knockdown of HSF1 after doxycycline-induced expression of the shRNAs.
Protein Isolation, SDS-PAGE, and Western Analysis
Cells were washed once and scraped in chilled PBS. After pelleting the cells,
protein was extracted using the M-PER lysis buffer (Thermo Scientific) with a protease
inhibitor cocktail (HaltTM Protease Inhibitors, Thermo Scientific). A Bio-Rad Protein
Assay was then utilized to quantify protein concentrations. 20 µg of lysate was resolved
on 8% to 12% sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDSPAGE) gels and transferred to Immun-Blot® 0.2µm PVDF Membrane with a Trans-Blot
semi-dry transfer cell (Bio-Rad). Membranes were blocked in 2% w/v non-fat milk in
TBS with 0.1% Tween (TBST milk). Blots were probed with primary and secondary
antibodies before incubation in ECL Prime Western Blotting Detection System
(AmershamTM) and film exposure. Primary antibodies used were: HSF1 (Assay
Designs), HSF1 P-S326 (Abcam) fibronectin (BD Biosciences), HSP90 (Cell Signaling),
HSP70 (Cell Signaling) and Actin (Santa Cruz). HRP-conjugated secondary antibodies
were from Millipore and Jackson ImmunoResearch.
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Cell Viability Assay
Cells at a concentration of 2 x 105 cells/ml were seeded in a 96-well plate at 100
µl per well with eight replicates for each test condition. The cells were then incubated
either with or without doxycycline treatment for 72 hours. After incubation, 10 µl of
PrestoBlue Cell Viability Reagent (Invitrogen) was added to each well and incubated for
1 hour at 37oC. The reduction of the reagent was measured by fluorescence (excitation
570 nm, emission 600 nm) using a microplate reader (BioTek). Mean percent viability
and standard error were then plotted.
Clonogenic Assay
Cells were seeded at 500 cells per well in 6-well plates and were treated with or
without 1 g/ml doxycycline to induce HSF1 knockdown. Treated wells were given an
additional treatment with 1 g/ml doxycycline on day 4 to maintain doxycycline levels.
After 8 days, colonies were stained with 1% crystal violet (w/v) in methanol and rinsed
3X in deionized water. Stained colonies were subsequently photographed and counted.
Wound Healing Assay
Cells were plated at 3 x 105 cells per well in a 6-well plate, and then either
treated with 1 g/ml doxycycline 48 hours prior to the assay or left untreated. Once the
cells reached confluency, a 2 µl pipet tip was used to scrape the cells in 2 vertical and 2
horizontal lines yielding 4 intersections per well. Cells were washed twice with PBS to
remove debris and serum-free medium was added. Pictures were taken immediately
and again 12 hours after the creation of the wound, using an EVOS inverted microscope
(Advanced Microscopy Group). The experiment was performed in triplicate and wound
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closure was determined using TScratch software [282]. Significant differences were
calculated by ANOVA and Bonferroni post-hoc tests.
Cell Migration
For the transwell migration assay, cells were treated with or without 1 g/ml
doxycycline 48 hours prior to the assay to induce HSF1 knockdown, and cells were then
serum-starved 24 hours before performing the assay. Cells were then resuspended in
serum-free medium, and seeded at 2.5 x 104 cells per upper chamber. 400 L of
complete medium containing FBS was added as a chemoattractant to the lower
chamber. After a 16-hour incubation, non-migrating cells on the upper surface of the
filter were removed by scrubbing with a cotton swab. The remaining cells on the lower
surface were fixed and stained with 1% (w/v) crystal violet in methanol. Migrated cells
were counted from 10 random fields of view from each well and each condition was
performed with triplicate samples. Statistical analysis done by paired t-test.
Spheroid Formation
The hanging drop method was utilized to form spheroids [283]. Briefly, cells
released with trypsin were resuspended at 1 X 106 cells/mL in RPMI medium,
supplemented as described above. Cell suspension droplets of 25 µl were placed on
the plate lids, which were then inverted and put back on plates containing phosphate
buffered saline (PBS) and incubated for 48 hours. Upon incubation, cells aggregated
into spheroids. Prior to plating the cells, TGFβ1 was added to the suspension as
indicated at a final concentration of 5 ng/mL. Following aggregation for 48 hours,
spheroids were collected in 1X PBS. Pictures were obtained using an EVOS
(Advanced Microscopy Group) inverted microscope.
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Quantitative RT-PCR
Cells were harvested in cold 1X PBS and RNA extraction was completed utilizing
the TRIzol reagent (Thermo Fisher) according to standard protocol. Reverse
transcription reactions of the RNA were performed with the High Capacity cDNA
Reverse Transcription Kit (Applied Biosystem), as per the manufacturer’s protocol. The
cDNA samples were then used as a template for qRT-PCR. Applied Biosystem’s Step
One Plus Real-time PCR machine was used with BioRad’s iTaqTM Fast SYBR® Green
Supermix with ROX according to the manufacturer’s protocol. The primer sets used for
each gene can be found in Table 3.1. GAPDH was used as the endogenous reference
control. Statistical significance was measured by Student’s t test.
Results
HSF1 is Overexpressed in Ovarian Cancer
We analyzed data from The Cancer Genome Atlas (TCGA) database to compare
HSF1 levels across multiple cancer types. Interestingly, we find that HSF1 gene
duplication is more common in ovarian cancer than in any other cancer type in this
database by a large margin (Fig. 3.1A). Additionally, we find that HSF1 mRNA
transcripts are elevated in ovarian cancer tumor tissue vs. normal epithelial tissue from
matched patient samples (Fig. 3.1B). Other cancers with high HSF1 mRNA levels
include liver cancer, head and neck cancer, and breast cancer (Fig. 3.1B). Two distinct
data sets of matched ovarian tumor tissue vs. normal tissue show that HSF1 mRNA
expression is significantly higher in tumor tissue (Fig. 3.1C-D). Given this data, we
postulate that HSF1 may drive ovarian cancer progression. We thus sought to study the
effect of HSF1 knockdown in ovarian cancer cell lines.
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Establishment of SKOV3 and HEY Inducible HSF1 Knockdown Ovarian Cancer Cell
lines
We chose two epithelial ovarian cancer cell lines for our studies, SKOV3 and
HEY. These cell lines were authenticated by using short tandem repeat (STR) DNA
profiling (Genetica, Inc.) and comparing the profiles to ATCC profiles and other
previously published profiles [232]. We first wanted to test whether the cell lines we
selected exhibited a normal response to heat, including the characteristic activation of
HSF1 and induction of chaperones. We find that both SKOV3 and HEY cells exhibit
multiple hallmarks of activation of the heat shock response (Fig. 3.2A). Upon treatment
with a 42C heat shock over a 6 hour timecourse, we observe stress-induced
hyperphosphorylation of HSF1 followed by a return to the hypophosphorylated state.
This result is characteristic of HSF1 activation by heat shock and can be readily
detected by electrophoretic retardation on SDS-PAGE and Western blot analysis [284].
Interestingly, while SKOV3 cells contain a similar level of basal and activated HSF1 as
compared to normal ovarian epithelial T80 cells, HEY cells express higher levels of
HSF1, corresponding to the higher levels of HSF1 expression we identified in ovarian
cancer patient databases. Upon heat shock, we also observed that both SKOV3 and
HEY cells show HSF1 phosphorylation at serine 326, a marker of activated HSF1 [3].
Additionally, the chaperone HSP70 was induced by heat shock in both SKOV3 and HEY
cells, and HSP90 was induced in HEY cells. Overall, we conclude that both SKOV3
and HEY cells express HSF1 and respond to heat shock, validating the choice of these
two ovarian cancer cell lines for our studies.
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We next wanted to generate HSF1 knockdown SKOV3 and HEY cell lines. Our
initial attempts to create stable HSF1 knockdown in these cell lines were not successful,
perhaps due to selective pressure for the cancer cells to re-express HSF1. We
therefore employed a doxycycline-inducible shHSF1 system (pTRIPZ vector, Open
Biosystems). To ensure that doxycycline treatment alone would not alter HSF1 levels
or activity, we treated SKOV3 and HEY cells with both 0.5 and 2.0 g/ml of doxycycline
for 48 hours and found no changes in HSF1 levels or hyperphosphorylation status (Fig.
3.3). We also found no change in HSP90 levels (Fig. 3.4). We therefore concluded that
a doxycycline-inducible system would be a viable option for HSF1 knockdown in our
studies.
We used two shHSF1 sequences obtained from the RNAi codex database [281],
shHSF1A (CGCAGCTCCTTGAGAACATCAA) and shHSF1B
(CCCACAGAGATACACAGATATA), as well as a control sequence that is non-targeting,
to create SKOV3.shControl, SKOV3.shHSF1A, SKOV3.shHSF1B, HEY.shControl,
HEYshHSF1A and HEY.shHSF1B stable cell lines (Fig. 3.2B). The shHSF1A sequence
knocks down HSF1 expression by about 75%, while shHSF1B knocks down HSF1
expression more completely. Knockdown of HSF1 resulted in only a marginal reduction
of cell viability in the SKOV3 or HEY cell lines over a 72 hour doxycycline treatment
timecourse (Fig. 3.2C). We thus have established an effective means of knocking down
HSF1 to varying degrees in two different ovarian cancer cell lines.
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HSF1 Knockdown Inhibits Colony Formation, Wound Healing, Cell Migration and
Fibronectin Expression
We then assayed our HSF1 knockdown cell lines to determine whether HSF1 is
important for ovarian cancer tumorigenicity. As a measure of the ability of HSF1 to allow
cell survival and growth upon plating at a low cell density, clonogenic assays were
performed (Fig. 3.4). SKOV3.shControl, SKOV3.shHSF1B, HEY.shControl and
HEY.shHSF1B stable cells were treated with or without doxycycline to induce HSF1
knockdown and then plated at 250 cells per well in 6-well plates in triplicate. Colonies,
stained after 8 days, show that HSF1 knockdown strongly inhibits colony formation in
both HEY and SKOV3 cells.
To assess the ability of HSF1 to affect cellular motility, we used a wound healing
assay as well as a cell migration assay. For the wound healing assay, cells were
seeded in equal numbers into 6-well plates and grown to ~80% confluence prior to
introducing scratches in straight lines through the monolayers. TScratch software was
then used to automatically analyze wound healing rates (Fig. 3.5A). HSF1 knockdown
in SKOV3 and HEY cells inhibits wound-healing ability by 25% and 28%, respectively.
Next, cell migration assays were employed to assess the ability of cells to pass through
a matrigel-coated transwell membrane (Fig. 3.5B). Cells were seeded in equal numbers
into the insert of a transwell plate, with no cells in the lower chamber. The number of
cells that passed through the membrane were then calculated and plotted after 48 hrs.
HSF1 knockdown was found to inhibit cell migration by 29% in SKOV3 cells and 33% in
HEY cells. These experiments in sum support a role for HSF1 in promoting cell motility
in ovarian cancer.
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We next wanted to test whether HSF1 knockdown can suppress the EMT
process. Fibronectin, a mesenchymal marker, is upregulated during EMT and plays a
crucial role in altering cell adhesion and migration processes, allowing for transition to
the mesenchymal state [36]. We tested protein expression levels of fibronectin using
Western blot analysis of SKOV3.shHSF1B and HEY.shHSF1B cells treated with and
without doxycycline and with and without the EMT inducer TGF (Fig. 3.5C). As
expected, TGF treatment induces fibronectin expression (Fig. 3.5C, compare lanes 1
with lanes 3). Interestingly, HSF1 knockdown in both SKOV3 and HEY cells reduces
both the basal expression levels of fibronectin (Fig. 3.5C, compare lanes 1 and 2) as
well as the TGF-induced levels of fibronectin (Fig. 3.5C, compare lanes 3 and 4).
Therefore, HSF1 may promote the EMT process by enhancing TGF-induced
fibronectin expression.
The Induction of Fibronectin by TGF is Enhanced in 3D Cultures as Compared to 2D
Cultures
As ovarian cancer cells typically spread throughout the peritoneal cavity in the
form of 3D spheroids, we cultured cells in 3D culture using the hanging drop method
[235] in order to create a more biologically-relevant in vitro system for our studies. We
first tested whether the induction of fibronectin by TGF is altered in 3D cultures as
compared to 2D cultures. In both monolayer and spheroid SKOV3 cells, TGFβ
increased fibronectin expression (Fig. 3.6). Surprisingly, this effect was enhanced in the
SKOV3 spheroid model as compared to monolayer cells (Fig. 3.6, compare lanes 2 and
4). The HEY cells also showed enhanced fibronectin expression upon 3D growth,
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although this effect was not enhanced by TGF. Therefore, we conclude that 3D
culturing enhances fibronectin expression.
3D Culturing Reveals a Marked Effect of HSF1 on the Induction of EMT Transcription
Factors
Various transcription factors, including snail, slug, twist, and zeb, help to
coordinate the EMT process [277]. We tested whether 3D growth affected the
expression of these genes (Fig. 4.6). We find that 3D growth enhances TGF induction
of these transcription factors as shown by qRT-PCR (Fig. 3.7, compare lanes 2 and 4).
We wondered whether HSF1 may regulate the expression of these EMT transcription
factors. We thus tested our HSF1 knockdown cell lines, grown under both 2D and 3D
conditions, to test for effects on the expression of SNAIL, TWIST1, SLUG and ZEB1
mRNAs (Fig. 3.7). SKOV3.shControl, SKOV3.shHSF1B, HEY.shControl, and
HEY.shHSF1B stable cell lines, grown both as 2D and 3D cultures, were treated with
and without doxycycline treatment to induce HSF1 knockdown. We find that HSF1
knockdown in most cases slightly inhibits the expression of EMT transcription factors in
SKOV3 and HEY cells grown in 2D (Fig. 3.7, compare lanes 2 with lanes 3).
Interestingly, the effect of HSF1 knockdown on the expression of these genes is
magnified for most of the genes upon growth in 3D conditions (Fig. 3.7, compare lanes
4 with lanes 5). Therefore, using a 3D ovarian cancer culturing system, we have
uncovered a positive effect of HSF1 on the ability of TGF to induce EMT genes. We
thus conclude that HSF1 promotes EMT in ovarian cancer 3D spheroids at least in part
through regulating the levels of EMT-inducing transcription factors.
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Discussion
As ovarian cancer is highly lethal and has few treatment options, identifying new
therapeutic targets for this disease is highly important. Through mining patient data, we
find that HSF1 DNA levels are most highly amplified in ovarian cancer as compared to
other cancers, and also that ovarian cancer is one of the top cancer types with amplified
HSF1 mRNA levels. A previous study of 37 malignant vs. benign ovarian tumors has
shown that HSF1 expression is higher in the malignant tumors [223]. Our findings thus
add to this data and suggest that HSF1 may be an important therapeutic target for
ovarian cancer.
We have identified HSF1 as a critical player in promoting ovarian cancer
tumorigenicity by multiple measures in both SKOV3 and HEY ovarian cancer cells. Via
HSF1 knockdown and colony formation assays, we show that HSF1 promotes the ability
of cells to grow under conditions of low cell density, a hallmark of cancer cells. Cell
motility is another characteristic of cancer cells. Previous work has shown that cell
motility is inhibited in immortalized mouse embryonic fibroblast cells derived from hsf1 /- mice [285]. In addition, HSF1 knockdown reduces the invasiveness of multiple types
of tumor cells [212, 214, 286-288]. Consistent with these findings, we show that HSF1
knockdown inhibits wound healing and cell migration in SKOV3 and HEY ovarian
cancer cell lines. Our results thus add further evidence that HSF1 enhances
tumorigenicity in multiple types of cancer.
EMT is essential for cell migration and is a key rate-limiting step in metastasis.
Previous studies have shown that HSF1 promotes EMT in breast cancer cells through a
mechanism that requires HER2 [289, 290]. As ovarian cancer cells typically spread
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throughout the peritoneal cavity in the form of 3D spheroids [74], culturing ovarian
cancer cells as spheroids is likely to better mimic the in vivo growth conditions as
compared to conventional 2D culturing conditions. Here, we show that HSF1
knockdown reduces the ability of TGF to induce EMT. Interestingly, we find that this
effect is stronger upon growth in 3D spheroids. We also show that HSF1 is required for
the compact morphological structure of spheroid growth.
Our data suggests that HSF1, either directly or indirectly, controls the expression
of transcription factors that are important for the EMT process. Interestingly, upon
promoter analysis, we find consensus heat shock element (HSE) sequences containing
three inverted arrays of the sequence nGAAn [291] in the promoters of the EMT
transcription factor genes SNAIL, ZEB and TWIST1 (Table S2). Putative HSEs are also
present in the FN1 (fibronectin), VIM (vimentin), and CDH2 (N-cadherin) promoters,
additional genes that are associated with EMT (Table 3.2). Future experiments will be
required to determine whether any of these genes are direct HSF1 targets. This is
plausible given that HSF1 was recently found to bind to the SLUG promoter through an
imperfect HSE motif [289].
In summary, we have identified HSF1 as a critical player in ovarian cancer
progression, and have identified EMT as a process that is promoted by HSF1. The
effects for HSF1 are more striking when cells are grown as 3D spheroids, which more
closely mimic the in vivo growth conditions of ovarian cancer. Therefore, HSF1
deserves further research and development as a promising anticancer strategy for
ovarian cancer.
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Figure 3.1. HSF1 Levels are Elevated in Ovarian Cancer Patient Samples.
A, HSF1 copy number is increased most frequently in ovarian cancer. HSF1 copy number was
analyzed in a variety of cancers using TCGA data and GISTIC analysis with a threshold CNA
change of +/-2. B, HSF1 transcripts are elevated in a variety of cancers. Samples from tumor
tissue and matched normal tissue were compared in the TCGA database using RNA Seq V2
RSEM data with a z-score threshold of +/-2. C, HSF1 is increased at the mRNA level in an
ovarian cancer data set GSE18520 consisting of 10 normal ovarian samples and 53 late stage,
primary site, high grade ovarian cancer samples. D, HSF1 is increased at the mRNA level in a
TCGA ovarian cancer data set consisting of 8 normal ovarian samples and 568 ovarian cancer
samples.
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Figure 3.2. Validation of Inducible HSF1 Knockdown Ovarian Cancer Cell Lines.
A, The heat shock response in the epithelial ovarian carcinoma cell lines SKOV3 and HEY as
compared to normal ovarian epithelial T80 cells. T80, SKOV3, and HEY cells were treated with
o
a 42 C heat shock for the indicated times and harvested immediately after. Cell lysates were
subjected to Western blot analysis using antibodies recognizing HSF1, HSF1 phosphorylated
at S326, HSP90, HSP70, and actin as a loading control. B, The pTRIPZ system was used to
create the doxycycline-inducible HSF1 knockdown cell lines SKOV3.shHSF1A,
SKOV3.shHSF1B, HEY.shHSF1A and HEY.shHSF1B. After treatment with 1 µg/ml
doxycycline for 48 hours, cell lysates were subjected to Western blot analysis using antibodies
recognizing HSF1 and actin as a loading control. Both short and long exposures are shown
for the HSF1 blot. C, HSF1 knockdown does not cause a large decrease in cell viability. The
viability of the SKOV3.shHSF1B and HEY.shHSF1B cell lines as compared to shControl cells
was assessed after treatment with 1 µg/ml doxycycline for the indicated times using the
PrestoBlue cell viability assay. Mean percent viability (n=8) and standard error is shown.
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Figure 3.4. HSF1 Knockdown Reduces Colony Formation.
SKOV3.shHSF1B, HEY.shHSF1B and control cell lines were plated 250 cells per well in 6-well
plates in triplicate. Cell were treated with or without 1 µg/ml doxycycline (Dox) to induce HSF1
knockdown and were given an additional dose after 4 days. Cells were stained with crystal
violet after 8 days to visualize colonies.
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Cell Invasion

Figure 3.5. HSF1 Knockdown Inhibits Wound Healing, Migration, and Induction of
Fibronectin.
A, HSF1 knockdown reduces wound closure. Cells treated with or without 1 µg/ml doxycycline
were grown in 6-well plates to confluency. Cells were scraped to create wounds, the cells were
washed and serum-free media was added. The intersections of perpendicular scratches were
photographed immediately and 12 hours after and analyzed using Tscratch software. Asterisk
denotes significant difference from all other samples calculated by ANOVA (P <0.05). B, HSF1
knockdown reduces migration. After treatment with or without 1 µg/ml doxycycline and 12 hours
4
of serum starvation, cells were added to a Boyden chamber at 2.5 x 10 cells per chamber.
Serum was used as the chemoattractant in the lower chamber. After 16 hours, nonmigrating
cells were scrubbed and cells which had migrated stained. The experiment was done in
triplicate and analysis done by paired t-test. Asterisk marks significant difference (P < 0.05). C,
HSF1 KD reduces TGFβ-induced expression of fibronectin.
SKOV3.shHSF1B and
HEY.shHSF1B were treated with 1ug/ml doxycycline, 10 ng/µl TGFβ, or both, and cell lysates
were harvested for immunoblotting. Cell lysates were subjected to Western blot analysis using
antibodies recognizing fibronectin, HSF1, and actin as a loading control.
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Figure 3.6. Fibronectin Expression is induced by 3D Growth.
SKOV3 and HEY cells were cultured under 2D or 3D conditions, with or without TGFβ, as
indicated. Cell lysates were subjected to Western blot analysis using antibodies recognizing
fibronectin, and actin as a loading control.
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Figure 3.7. TGFβ Induction of EMT Master-Switch Transcription Factors are Reduced
upon HSF1 Knockdown, and the effect is enhanced upon 3D Culturing.
Quantitative real-time polymerase chain reaction (qRT-PCR) of selected genes shows that the
EMT master-switch transcription factors SNAI1/SNAIL, TWIST1, ZEB1, and SNAI2/SLUG are
upregulated when HSF1 inducible knockdown SKOV3.shHSF1B and HEY.shHSF1B cells are
cultured as 3D spheroids. This effect is significantly reduced upon knockdown of HSF1 via
doxycycline treatment. Gene expression was normalized to the housekeeping gene GAPDH,
and fold change was calculated relative to monolayer non-treated conditions. Statistical
significance was measured by Student’s t test as compared to untreated monolayer cell culture
(*p<0.05; **p<0.01 ; ***p<0.001). Experiment performed with biological and technical
triplicates.
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Table 3.1. List of Primers used in Quantitative RT-qPCR.
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Table 3.2. Locations of HSEs in EMT Genes.
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CHAPTER FOUR: DISCUSSION AND FUTURE DIRECTIONS

Overview of Major Findings
We have shown that gene expression profiles significantly change upon three
dimensional spheroid culturing when compared to two dimensional monolayers. Using
the HEY ovarian cancer cell line, we show that 3D growth affects DNA integrity
pathways, stem cell differentiation, epigenetic pathways, and stress pathways. Namely,
transcripts that included Coiled-Coil Domain Containing 80 (CCDC80), Solute Carrier
Family 6 (Neutral Amino Acid Transporter), Member 15 (SLC6A15), Semaphorin 3E
(SEMA3E) and PIF1 5'-To-3' DNA Helicase (PIF1) were downregulated more than 10fold in the 3D cells while Inhibitor Of DNA Binding 2, HLH Protein (ID2), Regulator Of
Cell Cycle (RGCC), Protease, Serine 35 (PRSS35), and Aldo-Keto Reductase Family 1,
Member C1 (AKR1C1) were increased more than 50-fold.
Several of the above genes have been implicated in increasing tumorigenicity,
including upregulation of AKRC1C and PRSS35, in addition to a reduction in CCDC80
expression. More specifically, AKR1C1 expression has been linked to cisplatin
resistance in ovarian cancer cells [237]. PRSS35, a serine protease, may be
responsible for proteolytic digestion of cell attachment and thereby promote EMT in
ovarian cancer. Lastly, CCDC80 has been shown to be reduced in human ovarian
cancer samples compared to normal tissue. This is likely due to its role in inducing E –
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cadherin [240], which is responsible for promoting an epithelial phenotype by enhancing
cell-cell adhesion [241].
Novel pathways which were affected upon spheroid culturing included branched
chain amino acid metabolism, folate biosynthesis, mevalonate pathway, and fatty acid
oxidation. Branched chain amino acids, such as leucine, positively regulate the
mammalian-target-of-rapamycin (mTOR) pathway [242]. FRAP/mTOR inhibition has
been shown to reduce cancer cell growth in PTEN null cells [292]. Mutations in PTEN,
a known tumor suppressor which regulates signaling through the PI3-kinase/Aktsignaling pathway, are seen in several cancer cell types. Consequently, recent ovarian
cancer clinical trials have focused on molecular agents which target the
P13K/Akt/mTOR pathway. Another possible target is folate and its membrane-bound
folate receptors (FRs). Folate plays a role in nucleotide synthesis and methylation,
making it essential to cancer cells for DNA replication. Analysis of 104 human ovarian
carcinomas revealed 83% overexpressed alpha-folate receptor protein at moderate to
high levels compared to 0% in non-neoplastic ovaries [293]. Therefore, antifolate and
FR agents such as thymidylate synthase inhibitors, antifolate receptor antibodies, and
folate-chemotherapy conjugates may have anti-tumor affects in ovarian cancer [294].
Conversely, the mevalonate pathway converts acetyl-coenzyme A into isoprenoids,
which are vital for cholesterol synthesis. Low-density lipoprotein (LDL) cholesterol has
been shown to collect in cancer tissues and increased levels have been linked to
proliferation and migration [246].
Related specifically to stress pathways, networks involved in oxidative stress,
DNA damage response, and heat shock response were all altered upon three
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dimensional spheroid culturing methods. This is not shocking since it is known that
spheroid growth conditions may cause hypoxia and a reduction in nutrient and waste
transport. Gene expression changes related to oxidative stress included: Peroxiredoxin
2 (PRDX2), Catalase (CAT), Superoxide dismutase 1, soluble (SOD1), and Glutathione
S-transferase omega 1 (GST01). Oxidative stress promotes tumorigenic properties by
impacting important signaling cascades such as Ras, Raf, p53, PKC, and Nrf2 [250252]. This oxidation process guards cancer cells from ROS through the synthesis of
ATP and NADPH [245]. Related to oxidation, fatty acid oxidation is essential for
angiogenesis and enables cancer tumors to overcome metabolic stress [245]. This
makes fatty acid oxidation yet another potential target for cancer treatment.
DNA integrity responses, such as DNA damage, nucleotide excision repair
(NER), and genetic instability were also altered upon three dimensional spheroid
culturing. Microenvironment differences in the spheroid environment leads to hypoxia
and ROS which causes DNA damage and therefore mutagenesis. To identify and
repair this damage, mechanisms such as NER is utilized, which was enriched in our
analysis.
Our gene expression studies show significant changes in transcripts which are
related to the HSR, to include: heat shock protein 90kDa alpha (cytosolic), class A
member 1 (HSP90AA1), heat shock 27kDa protein 1 (HSPB1), and heat shock
transcription factor 1 (HSF1). Research has suggested that tumor progression for some
cancer types may heavily rely on HSF1, the master regulator of the HSR. In our TCGA
analysis, we revealed that HSF1 gene duplication is more common in ovarian cancer
than any other cancer type and that HSF1 mRNA transcripts are significantly elevated in
81

ovarian cancer tumor tissue compared to that of normal epithelial tissue derived from
the same patient.
Further analysis utilizing SKOV3 and HEY ovarian cancer cell lines shown that
HSF1 plays an essential role in promoting ovarian cancer tumorigenicity. HSF1
knockdown SKOV3 and HEY ovarian cancer cells were created utilizing a doxycyclineinducible shHSF1 system. We ensured that doxycycline treatment alone would not alter
HSF1 levels, HSF1 hyperphosphorylation status, or HSP90 levels.
Subsequent HSF1 knockdown diminishes cell invasiveness, mobility, and the
cells ability to grow without contact inhibition. First, a matrigel-coated transwell
membrane was utilized to determine that HSF1 knockdown inhibits cell migration in both
SKOV3 and HEY. Second, a wound healing assay showed that reduction in HSF1
correlates to the inhibition of cell mobility in order to effectively close implemented
scratches in monolayer cells. Lastly, focus assays proved that HSF1 knockdown
significantly reduces focus formation in HEY and SKOV3 ovarian cancer cells.
Knockdown of HSF1 also caused a reduction in Fibronectin, a mesenchymal marker
which is vital for the EMT process. Further analysis revealed that HSF1 knockdown
alters the expression of EMT transcription factor genes, SNAIL, ZEB, TWIST1, and
SLUG.
Utilizing the hanging drop method, we determined that three dimensional
culturing enhances TGFβs ability to induce EMT. Interestingly, this reduction in the
ability TGFβ to induce EMT in response to decreased HSF1 expression is significantly
stronger in three-dimensional spheroids. Therefore, we determined that HSF1
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promotes EMT in ovarian cancer spheroids through regulating EMT-inducing
transcription factor expression. In all, HSF1 is critical for ovarian cancer progression
and should be further studied for possible antitumor treatments.
Spheroids as a Therapeutic Model
Approximately 35% of ovarian cancer patients present with metastasized single
and aggregated ovarian cancer cells suspended within voluminous exudative fluid in the
peritoneal cavity, known as ascites [73]. This phenomenon has been linked to drug
insensitivity, amplified cancer progression, and reduced survival [74, 75, 295]. The
aggregated cells free floating within the ascetic fluid very closely mimic those created
utilizing spheroid cell culturing models. Therefore, spheroid culturing may be utilized to
fully characterize and determine the best possible chemotherapeutic techniques.
Future Studies for Ovarian Cancer Spheroids
Upon discovering a plethora of differentially expressed genes between
monolayer and spheroid cultured ovarian cancer cells, we suggest further exploration of
spheroid treatment in regard to the HSR. We hypothesize that novel HSF1-regulated
genes which are vital for EMT and ovarian cancer progression will be discovered. To
accomplish this, the focus should be on identifying HSF1 dependent genes that are
affected by ovarian cancer spheroid growth. First, target mRNAs that are regulated by
3D growth should be determined by mRNA-sequencing techniques with and without
doxycycline treatment for HSF1 knockdown. High-throughput sequencing would
determine genes which are induced in EMT in an HSF1 dependent fashion. Next, it
would be interesting to identify target miRNAs that are regulated by spheroid growth.
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miRNAs have been shown to be vital regulators in cancer progression and metastasis
and therefore are essential to understanding the mechanism behind HSF1’s role in
ovarian cancer progression. Lastly, ChIP-seq would identify direct HSF1 targets. This
would allow for the identification of HSF1 binding sites in gene promoters and other
regulatory sequences.
Further expanding on our knowledge of HSF1’s role in EMT, we propose
analyzing protein expression changes upon HSF1 knockdown during spheroid culturing
and identifying critical pathways in EMT and metastasis. This could be accomplished
by utilizing mass spectrometry to evaluate protein expression changes in spheroid cells
upon HSF1 knockdown. Analysis of global changes at the protein level is determined
through stable isotope labeling by amino acids in cell culture (SILAC). Then, results
would be evaluated via Pathway Studio™ to determine critical pathways and targets.
From there, it would be interesting to determine the role of critical HSF1 targets on EMT
through knockdown or overexpression of identified genes.
Implications for HSF1’s Role in Ovarian Cancer Progression
Several cancer cell types exploit HSF1’s survival properties in order to avoid
apoptosis and to proliferate. Elevated HSF1 expression has been shown in prostate,
breast, colon, and lung cancer, and is a biomarker for poor prognosis and tumor
progression [197, 215-217]. Increased expression of HSPs has been similarly linked to
a wide range of tumor histotypes and is linked to chemotherapy resistance and poor
prognosis. For instance, HSP90’s chaperone properties maintain the active
conformation of overexpressed or mutated signaling proteins which are vital for
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development and cell renewal within cancer tumors [296, 297]. Therapeutics which
target HSP90 cause morphological differentiation and apoptosis through G1 cell cycle
arrest [297]. Similarly, HSP70 correlates with metastasis and poor prognosis while
inhibition through anti-sense HSP70 cDNA causes proliferation inhibition and promotes
apoptosis [298, 299].
Therapeutically Targeting the HSR
Modulators of HSF1 and HSPs have been implicated in treatment of these
various diseases. For instance, HSP90 is an attractive target for cancer treatment and
several inhibitors of HSP90 are currently being studied in clinical trials [300, 301]. The
first HSP90 inhibitor was not discovered until 1994 when Whitesell et al. described the
natural product known as geldanamycin (GA) and its ability to bind HSP90’s adenosine
triphosphate pocket, causing degradation of client proteins such as the oncogene v-Src
[302]. HSP90 aids in the stability of client oncoproteins, which promotes cancer cell
progression [303]. HSP90 inhibitors cause ubiquitination and subsequent degradation
of these oncoproteins by binding to HSP90’s adenosine triphosphate pocket, rendering
it functionally inactive, and preventing client stabilization [187]. Compared to normal
cells, many cancer cells have elevated levels of the active HSP90 complex and are
selectively sensitive to inhibition of HSP90 [304, 305]. Today, there are several
synthetic, second-generation HSP90 inhibitors being studied for potential clinical use in
a wide range of human diseases. These inhibitors, such as ganetespib seen in Figure
4.1, are less toxic than their natural first-generation counterparts [306]. Currently there
are no agents targeting HSP90 which have been approved for clinical use, however
substantial progress has been made in the past decade towards this goal.
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Ganetespib (formally known as STA-9090) is a small molecule inhibitor of HSP90
which has superior anti-tumor effects and a superior safety profile as compared to first
generation HSP90 inhibitors [306]. Ganetespib is a resorcinol-containing triazole
compound developed by Synta Pharmaceuticals (Fig. 4.1). Thus far, the compound has
been studied in clinical trials involving non-small cell lung cancer, acute myeloid
leukemia, gastrointestinal stromal cancer, and metastatic breast cancer with mixed
results [307-311]. In ovarian cancer, ganetespib significantly inhibited tumor
progression and growth of orthotopic xenografts and spontaneous ovarian tumors in
mice. Additionally, paclitaxel enhanced this effect [312].
Celastrol, an active compound
derived from the Tripterygium wilfordii
Hook F plant (TWHF) was first
characterized by Westerheide et al. as
an inducer of the HSR (Fig. 4.1) [313].
More specifically, it induces HSPs in
multiple cell lines by inhibiting HSP90,
allowing for HSF1 activation which in
turn increases HSP expression [314].
Using this response, celastrol has been
shown to improve neurodegenerative
diseases such as ALS and Parkinson’s

Figure 4.1: Small molecule modulators of the
HSR and HSP90.
Both celastrol and ganetespib have been shown to
regulate the HSR by inhibiting HSP90, allowing for
HSF1 activation. Actinonin is a novel compound
which reduces celastrol’s HSR effects while
increasing its anti-tumor properties.

[315, 316]. This compound is also
capable of anti-tumor effects both in vitro and in vivo across multiple histological origins
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[317, 318], likely due to it arresting cell cycle progression and inducing apoptosis as
seen with other HSP90 inhibitors [319]. However, like other HSP90 inhibitors,
celastrol’s ability to induce the HSR is an unwanted effect when applying it to cancer
treatment, since enhancing HSP levels increases tumor cell survival. Recently, the
addition of the peptide deformylase inhibitor, actinonin, to celastrol-treated cancer cells
showed a synergistic effect by reducing the HSR while enhancing proliferation inhibition
[320]. Actinonin also has anti-tumor activity in vitro and in vivo for a number of cancer
subtypes, however the exact mechanism has not been fully characterized [321].
Future in vitro Studies for Targeting the HSR in Ovarian Cancer
To build on our current studies, in vitro assays examining HSF1’s mechanistic
role in EMT as well as assays examining potential synergistic effects of HSF1 and
HSP90 small molecule modulators with standard chemotherapy agents could be
conducted. We propose using ovarian cancer monolayer and spheroid model cells to
determine the mechanism for HSF1 regulation of EMT transcription factor genes and
subsequent EMT-associated genes. To do so, one would first evaluate possible HSF1
binding in the promoter region of transcription factor genes SNAIL, ZEB, TWIST1, and
SLUG in addition to EMT associated genes FN1, VIM, and CDH2. This could be
accomplished through promoter studies using luciferase reporter plasmids to determine
if HSF1 can regulate these promoters. Another possible option to shed light on this
particular mechanism could be through HSF1 overexpression. Overexpression assays
could further validate the findings with HSF1 knockdown in ovarian cancer cell lines by
studying EMT gene and protein expression level changes. HSF1 overexpression
should induce opposite effects from HSF1 knockdown on proliferation, invasion, and
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EMT promotion. Yet another important factor is whether EMT gene or protein
expression levels vary throughout a heat shock time course. This may shed some light
on whether HSF1’s role in EMT is independent or dependent of its classical HSR
mechanism. We propose a study of mRNA and protein expression levels upon multiple
heat shock time courses to fully understand the mechanism behind the HSR and
ovarian cancer progression.
Due to limited ovarian cancer treatment options, compounded by the fact that
relapsed patents are no longer susceptible to the drugs previously administered, it is
vital to study ways to enhance treatment alternatives. We hypothesize that ovarian
cancer cells will prove to be more susceptible to the chemotherapy agents paclitaxel
and cisplatin upon treatment with small molecule modulators of HSF1 and HSP90 using
the three dimensional EMT model. Determining the effects of the chemotherapy agents
cisplatin and paclitaxel on ovarian cancer spheroid growth would accomplish this. Then
followed by assessing the effects of ovarian cancer spheroid treatment with HSP90 and
HSF1 small molecule modulators on apoptosis, cell proliferation, cell migration, and
critical EMT and HSR genes. Once this has been established, it would be worthwhile to
identify possible synergistic effects of combination treatments of chemotherapy drugs
and HSP90 and HSF1 modulators in three dimensional spheroids.
While both celastrol and ganetespib have been shown to have anti-tumor affects,
they also induce the HSR, which induces tumorigenicity. Reduction of HSR induction
could be accomplished with the addition of the antibacterial agent actinonin.
Interestingly, the addition of actinonin to celastrol-treated cancer cells showed a
synergetic effect by reducing HSR induction while promoting proliferation inhibition
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Figure 4.2: Proposed Combinational Treatment assay in 3D Spheroids.
Utilizing single treatments as controls, this experiment would analyze the effect of combining HSP90
and HSF1 small molecular modulators celastrol and ganetespib with standard chemotherapy agents,
cisplatin and paclitaxel. Then, possible further synergistic effects are tested with the addition of
actinonin, which may reduce induction of the HSR. Each sample type would be assessed for effects
on viability, cell proliferation, cell migration, and critical EMT and HSR genes.

[320]. Figure 4.2 displays possible treatments which could be assayed to determine
any possible synergistic combinations. After treatment, the spheroids could be tested
for the effects on viability, cell proliferation, cell migration, and expression of EMT and
HSR genes.
Another proposed alternative method for inhibiting HSP90 without inducing the
cytoprotective effects of the HSR are newly developed C-terminal HSP90 modulators
[322]. These compounds inhibit specific co-chaperone binding to the methionineglutamic acid-glutamic acid-valine-aspartic acid (MEEVD) region of HSP90 while
reducing HSP27, HSP40, and HSP70 expression levels in pancreatic, colon, and
cervical cancer cells [323, 324]. Previously, C-terminal targeting agents such has
Novobiocin and KU174 have been shown to reduce HSP90 activity without HSR
induction, however these compounds may not be suitable for pre-clinical trials due to
potency and solubility factors [325, 326]. Recently, Armstrong et al. described the novel
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HSP90 inhibitor SM258’s ability to significantly reduce proliferation in ex vivo cultured
human prostate tumors without inducing the HSR [327]. As an alternative approach, we
propose comparing SM258’s activity in ovarian cancer spheroids to the proposed
combinational treatment above. The lack of information regarding this compound’s
toxicity and potential off-target affects is a limiting factor in this experimentation.
Although initial response to traditional chemotherapy agents is over 80%, a
majority of women ultimately relapse and develop drug-resistant ovarian cancer.
Therefore, there is a strong need for second-line chemotherapeutic options. We
propose to evaluate the response to HSP90 and HSF1 modulators in chemotherapyresistant ovarian cancer cell lines. First, one could create cisplatin or paclitaxel
resistant SKOV-3 and HEY ovarian cancer cells lines through a series of chemotherapy
treatments. Next, one could determine the effect of resistance on the cells’ ability to
form spheroids and test the effect of resistance on the cells’ ability to respond to HS and
what changes this has on HSP mRNA and protein expression. This could then lead to
evaluating the possibility of re-sensitizing resistant cells utilizing HSP90 and HSF1
modulators in combination with chemotherapy agents. Experiments should be
performed at least in biological duplicate with technical triplicates. Student t test can be
used for comparisons between two groups and one-way ANOVA analysis can be used
for comparisons among three or more groups. P< 0.050 would be considered
significant. Through these experiments, we can expand our understanding of HSF1’s
role in ovarian cancer and how it may be utilized as a novel therapeutic target.
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Future in vivo Studies for Targeting the HSR in Ovarian Cancer
To further expand our knowledge of HSF1’s role in ovarian cancer progression
within a whole organism, it would be interesting to assess these affects using a mouse
model. First, CMV-driven luciferase stable cell lines SKOV3.shHSF1B/Luc and
HEY.shHSF1B/Luc could be established and grown as three dimensional spheroids.
These spheroid cells could be
injected directly into the
intraperitoneal cavity of
immunosuppressed humanized
mice that have been treated
with doxycycline (0.5 mg/mL)
to knockdown HSF1 or left
untreated (Fig. 4.3).
Humanized mouse models
have a high engraftment
success rate while facilitating
human-like hematology and
immunology [328]. During
metastasis, ovarian cancer
cells commonly disassociate
with the primary tumor and

Figure 4.3: Proposed experimental outline to investigate
HSF1’s role in ovarian cancer progression and
metastasis. In this study, shHSF1 luciferase stable ovarian
cancer cell lines would be established and injected into the
peritoneal cavity of immunosuppressed mice. Tumor growth
and metastasis would be subsequently examined through
bioluminescence imagining and then further tissue analysis
would be performed after sacrificing the mice.

float within the peritoneal cavity before attaching to another organ and producing a
secondary tumor. Luciferase expression throughout the mouse could then be assessed
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utilizing an IVIS imaging system which would indicate tumor size and metastasis.
Metastasis is likely to occur within organs which reside in the peritoneal cavity, such as
the liver, colon, stomach, and kidney, and therefore should be the focus of this study.
The mice could then be sacrificed and various tissues analyzed for expression changes
in HSF1, HSP70, and previously discussed EMT markers. We hypothesize that HSF1
knockdown will cause a reduction in tumor growth and metastasis in vivo. While HSF1
knockdown has been shown to reduce tumor size in other cancer tumor types [207], this
experiment would determine what affects it may have for ovarian cancer in a whole
organism.
Patient-Derived Xenograft (PDX) ovarian cancer models are also available for in
vivo studies [329]. These xenograft tumors can be implanted into immunosuppressed
mice and retain the genetic and phenotypic characteristics found in human ovarian
cancer [329-331]. Ovarian cancer PDX models show a strong similarity to patient solid
tumors in cancer proliferation, metastasis, and ascites formation [332]. We propose
utilizing this model in conjunction with HSF1 and HSP90 small molecule modulators, as
described in the above, to further elucidate the effects of HSF1 and HSP90 inhibition on
ovarian cancer progression. However, this method can be limited by time and cost,
which may not make it a feasible option. Distinguishable tumor growth can take up to
eight months in PDX models and the cost to maintain and test these models can be
restrictive [333].
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Final Thoughts
These proposed studies investigating the in vivo and in vitro responses to
manipulating HSF1 expression will provide a more thorough understanding of HSF1’s
role in ovarian cancer progression and EMT. This may offer a detailed mechanistic
outline of how ovarian cancer relies on HSF1 to proliferate and progress. Specific
insight on this role could lead to breakthroughs in current treatment options.
Additionally, we hypothesize that combining HSR modulators with standard
chemotherapy agents may lead to a synergistic effect on inhibiting ovarian cancer cell
progression in the spheroid model by reducing proliferation, metastasis, and cell
viability. It is yet unknown which combination will result in the most efficient anti-tumor
properties, but we anticipate this approach to be closely related to the actual in vivo
response that would be seen in ovarian cancer patients. Furthermore, we believe that
expanding this research through the use of a whole organism model will solidify our in
vitro findings of HSF1’s vital role in ovarian cancers progression and metastasis.
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APPENDICES
Appendix A: Protocols
Counting and Passaging Cells
1. Warm complete media and Trypsin in 37oC water bath for 30 minutes and
prepare hood
2. Tilt plate and aspirate off media without touching the bottom of the plate
3. Add 1X PBS1 to plate and rock gently
4. Aspirate off 1X PBS
5. Add trypsin2 to plate, rock gently, and place into 37oC incubator for 5 minutes
6. After 5 minutes, check cells under microscope to ensure they have completely
rounded and are no longer adhered to the plate
7. If cells are still adhered to the plate, place back in the incubator for 2 minutes
8. Add media3 to plate to inactivate trypsin
9. Pipette up and down to break up cell clusters
10. Add 50 µL of cells and 50 µL of trypan blue dye to a 1.5 mL microcentrifuge tube
11. Pipette 10 µL of cell mixture to a hemocytometer slide
12. Under the microscope, count 2 boxes of 4x4 squares (Fig. A1)
a. If total of two boxes is 103, then cell count is 1.03 x 106 cells/mL
13. Calculate the appropriate dilution to reach the desired cell concentration
a. Usually dilute to 75,000 cells per mL
b. I.E. (5 mL cells / total number cells counted * 75,000 cells)
14. Pipette the applicable cell and media volumes into the desired plate size
Table A1. Solution Volumes for Passaging
Solution
PBS1
Trypsin2
Media3

35mm Plate 60mm Plate
5mL
10mL
500µL
1000µL
5mL
10mL
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Figure A1. Cell Counting with Hemacytometer
Collecting Cells
1. Warm complete media and Trypsin in 37oC water bath for 30 minutes and
prepare hood
2. Tilt plate and aspirate off media without touching the bottom of the plate
3. Add 1X PBS1 to plate and rock gently
4. Aspirate off 1X PBS
5. Add trypsin2 to plate, rock gently, and place into 37oC incubator for 5 minutes
6. After 5 minutes, check cells under microscope to ensure they have completely
rounded and are no longer adhered to the plate
7. If cells are still adhered to the plate, place back in the incubator for 2 minutes
8. Add media3 to plate to inactivate trypsin
9. Pipette up and down to break up cell clusters
10. Collect all identical sample sets into a single conical
11. Spin down conical at 1200 rpm for 2 minutes
12. Aspirate off media, leaving the cell pellet remaining
13. Resuspend cell pellet in 500 µL of 1X PBS
14. Transfer cell solution to a new 1.5 mL microcentrifuge tube
15. Centrifuge for 5 minutes at 1200 rpm
16. Apirate off 1X PBS and use immediately or freeze at -80oC for future use
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Creating spheroids treated with TGFβ
1. Warm complete media and Trypsin in 37oC water bath for 30 minutes and
prepare hood
2. Wash cells in 60 mm plate with 10 mL 1X PBS and aspirate off
3. Add 1000 µL trypsin and place in 37oC incubator for 5 minutes
4. Suspend un-adhered cells in 5mL complete media
5. Place in 15 mL conical
6. Spin down at 1000 RPM for 2 minutes
7. Aspirate off media and leave the cell pellet
8. Resuspend in 4 mL complete media
9. Count cells with typan blue via the hemacytometer as described above
10. Dilute cells to concentration of 1x106 cells per mL place in boat
11. Take TGFβ from -80oC
12. Add 20µl of TGFβ in 4mL media (5µl per mL) directly to cells in boat
13. Prepare untreated 100 mm petri dishes by adding 5 mL 1X PBS to bottom
14. Set multichannel pipette to 20µl
15. Push down pipette to second stop, pull up completely, dispense only 20µl (first
stop)
16. Gently rock boat periodically for settlement
17. Flipping right side up, place the lid onto the bottom of the plate
18. Incubate at 37oC for 72 hours to allow for aggregation
Collecting Spheroids
1. Keep cells on ice during collection
2. Utilizing a 10 mL pipette, tilt plate lid, add 5 mL of chilled 1X PBS to the top cell
drop, and allow the subsequent drops to collect at the bottom of the lid
3. Repeat for each row of cell drops
4. Pipette spheroids from the plate into a 15 mL conical
5. Allow spheroids to settle at the bottom of the tube
6. Avoiding the collected spheroids, pipette approximately 4mL of the 1X PBS from
conical and repeat procedure for remaining plates
7. Spin down conical at 1000 RPM for 5 minutes
8. Aspirate off 1X PBS without disturbing cell pellet
9. Add 1000 µL 1X PBS to transfer to a 1.5 mL microcentrifuge tube
10. Centrifuge at 1000 RPM for 5 minutes
11. Aspirate 1X PBS, leaving a cell pellet
12. Use immediately or store in -80oC for further experimentation
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RNA extraction and sample processing for Affymetrix 3’IVT Expression System
1. Extract RNA from sample cell pellets according to Qiagen’s RNeasy Mini Kit
2. Verify RNA integrity with The Agilent 2100 Bioanalyzer
3. Convert RNA to cDNA and amplify/label with biotin using Affymetrix 3’IVT
Expression System
4. Complete the following steps according to Affymetrix technical manual:
a. Hybridization with the biotin-labeled RNA
b. Staining
c. Scanning of chips
5. Normalize data with Affymetrix Expression Console v1.3.1
6. Utilize Pathway Studio 9.0 and ResNEt 10.0 for sub-network enrichment analysis
of cell processes
Reverse transcription reaction
1. Make mastermix in 1.5 mL microcentrifuge tube
Table A2. Reagent Volumes for Reverse Transcription Mastermix
Reagent
10X RT Buffer
25X dNTPs
10X RT Random Primers
RT Enzyme
dH2O
Total

1 rxn
2.0
0.8
2.0
1.0
4.2
10 µL

5.5 rxn 10.5 rxn
11.0
21.0
4.4
8.4
11.0
21.0
5.5
10.5
23.1
44.1
55 µL
105 µL

2. Vortex and short spin
3. Transfer 10 µL of mastermix to 0.1 mL tubes
4. Add 10 µL of RNA solution to the 0.1 mL tubes
a. If necessary, dilute RNA with dH2O so it does not exceed 2 µg
5. Vortex and short spin
6. Run in thermocycler machine with the following conditions
Table A3. Temperature Conditions for Reverse Transcription Reaction
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Temperature
25oC
37oC
85oC

Time (min)
10
120
5

Real-Time Quantitative PCR with SYBR Green
1. Set computer cycle parameters
Table A4. Temperature Conditions for RT-qPCR
Temperature
95oC
95oC
55-60oC

Time (seconds)
45
3
30

X 35-45 cycles

2. Made a working stock of 50 ng/µL template cDNA
3. Add 1 µL of template DNA to wells in vertical triplicate sets
4. Create master mix in a 1.5 mL microcentrifuge tube
Table A5. Reagent Volumes for RT-qPCR Mastermix
Reagent
SYBR green + ROX
Forward Primer
Reverse Primer
dIH2O
Total
5.
6.
7.
8.
9.

1 rxn (1 well)
10.0
0.2
0.2
8.6
20 mL

3.3 rxn (3 wells)
33.0
0.66
0.66
29.38
66 mL

Vortex and short spin
Transfer 19 µL of master mix to subsequent wells
Cover and seal plate with adhesive and short spin
Place plate in RT-qPCR machine and start run
After run is complete, analyze relative gene expression via the 2-ΔΔCt method with
GAPDH serving as an endogenous control for normalization as well as
normalization to the untreated control cell samples
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PrestoBlue Cell Viability
1.
2.
3.
4.
5.

Load 96 well plate wells with 90 µL of cell solution
Add compound in serial dilutions and incubate at 37oC for prescribed time
Pipette 10 µL PrestoBlue to each well
Incubate plate 37oC for 20 minutes - 2 hours
Measure by fluorescence at 570 nm excitation and 600 nm emission using a
microplate reader (BioTek)
6. Normalize sample well average to control average
7. Plot data points and standard error appropriately

Western Blot Analysis
SDS-PAGE Gels
1. Prepare BioRad gel apparatus by setting up the casts
2. Make up the desired percentage separating gel in a conical and immediately
pour it into ¾ of the cast
3. Pipette 1 mL of hydrated butanol over the separating gel solution
Table A6. Reagent Volumes for Separating Gel
Separating Gel
Reagent
8%
10%
5.3 mL
4.8 mL
dH2O
2.5 mL
2.5 mL
1.5 M Tris (pH 8.8)
2.0 mL
2.5 mL
40% Acrylamide
100 µL
100 µL
10% SDS
100 µL
100 µL
10% APS
4 µL
4 µL
TEMED*
*Add TEMED component last

12%
4.3 mL
2.5 mL
3.0 mL
100 µL
100 µL
4 µL

4. Allow separating gel to set for 30 minutes
5. Decant off hydrated butanol and rinse with dH2O
6. Make up the stacking gel, immediately pour it into the remaining ¼ cast, and
insert the desired comb
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Table A7. Reagent Volumes for Stacking Gel
Stacking Gel
Reagent
4%
7.3 mL
dH2O
1.25
mL
1.5 M Tris (pH 8.8)
1.25 mL
40% Acrylamide
100 µL
10% SDS
100 µL
10% APS
10 µL
TEMED*
*Add TEMED component last
7. Allow stacking gel to set for 30 minutes
8. Remove comb, rinse wells with dH2O, place into electrophoresis chamber, and
cover with running buffer
Sample Preparation
1.
2.
3.
4.
5.

Add laemmli buffer with beta-mercaptoethanol to normalized samples
Denature the proteins by incubating at 95oC for 5 minutes
Vortex, short spin, and load each sample as desired into the gel
Add laemmli buffer to any unused wells
Run the gel at 180V until the dye front just runs off the gel

Blotting
1.
2.
3.
4.

Remove gel from apparatus
Carefully detach the stacking layer from the separating layer
Activate PVDF membrane in 100% methanol for 1 minute
Assemble the blot in a large tray of transfer buffer accordingly:
Blotting Paper
PVDF membrane
Separating gel
Blotting Paper

Figure A2. Western Blotting “Sandwich” for Transfer to Membrane
5. Invert the blot assembly and place on the semi-dry transfer machine
6. Run one gel at 300 mA for one hour and two gels for 90 minutes
7. Briefly stain with 0.1% Ponceau solution and then rinse with dH2O to visualize
protein bands and confirm equal loading
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8. Add 1-2 drops of NaOH to 5 mL of TBST and incubate the membrane for 30
seconds in this solution to dissipate Ponceau staining

Antibody Staining and Detection
1. Block membrane by rotating at RT in TBST with 5% non-fat dry milk for 30
minutes
2. Rinse in TBST at RT for 30 seconds
3. Incubate the membrane in primary antibody diluted in TBST with 1% non-fat dry
milk rotating overnight at 4oC
4. Wash the membrane in TBST for 15 minutes rotating at RT and repeat a total of
three times
5. Incubate the membrane in secondary antibody diluted in TBST with 5% non-fat
dry milk rotating for 1½ to 2 hours at RT
6. Turn on western blot exposure machine to allow it to warm up for a minimum of
25 minutes
7. Wash the membrane in TBST for 5 minutes rotating at RT and repeat a total of
three times
8. Place the membrane on a transparency sheet taped into a cassette
9. Pipette 1 mL of ECL solution (prepared as per box instructions) onto each
membrane
10. Cover membrane to reduce light exposure and let incubate for 5 minutes at RT
11. Add another transparency sheet on top of the membrane and tape it down to the
cassette
12. In a dark room, expose the membrane to film and run through exposure machine
13. Label the film accordingly and turn off the machine when complete
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Western Blot Antibodies
Table A8. Primary Antibodies for Western Blot Analysis
Antibody
Actin
Fibronectin
HSF1 mono
HSF1 pS326
HSP70
HSP90

Primary Antibodies
Manufacturer
Cat #
Dilution
Santa Cruz
SC-1616-R 1:5000
Thermo Scientific MS-165-P0 1:1000
Assay Design
SPA-950
1:750
Abcam
EP1713Y
1:500
Stress Marq
SMC-100B
1:1000
Cell Signaling
8165
1:1000

Species
Rabbit
Mouse
Rat
Rabbit
Mouse
Rabbit

Location
4 oC
-20oC
-20oC
-20oC
-20oC
-20oC

Table A9. Secondary Antibodies for Western Blot Analysis
Species
Rabbit
Mouse
Rat

Secondary Antibodies
Manufacturer
Cat #
Millipore
PA45011V
Millipore
PA43009V
Jackson Immuno 112-035-062

Dilution
1:2500
1:2500
1:10,000

Location
-20oC
-20oC
4 oC

Doxycycline-Inducible TRIPZ shRNA HSF1 Knockdown Cell Creation
Day 1: Packaging Cells Preparation
1. Split cells so they are 50% - 70% confluency on the day of transfection
Day 2: Packaging Cells Transfection
1. Dilute 1 µg each of retroviral construct, pCGP, and pVSVG envelope plasmid
with cell media (without any additives) for a total volume of 300 µL per reaction
2. Vortex and short spin
3. Add 50 µL per reaction of Polyfect Transfection Reaction (Qiagen) to the DNA
solution
4. Vortex, short spin, and incubate at RT for 10 minutes
5. Aspirate media from cell plates
6. Wash in 5 mL of 1X PBS and aspirate off
7. Add 9 mL of complete media to cells
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8. Add 1 mL per reaction of complete media to the DNA solution after incubation
period
9. Pipette up and down and transfer 1350 µL of solution to each plate of cells
10. Gently rock each plate
11. Incubate at 37oC for 24 hours
Day 3: Replace Media and Target Cell Preparation
1. Replace transfection media with fresh complete media
2. Incubate at 37oC for 24 hours
3. Plate future transfected cells in 60 mm plate
Day 4: Collect Virus and Infect Target Cells
1. Warm complete media and 37oC water bath for 30 minutes and prepare hood
2. Collect virus media from packaging cells into a conical and replace with fresh
complete media
3. Incubate packaging cells at 37oC for 24 hours
4. Filter virus media through a 0.45 micron PVDF filter
5. Add equal volume of complete media to filtered virus media
6. Add 8 µg/mL of hexadimethrinebromide to virus media
7. Pipette 4 mL of virus media solution per plate to target cells
8. Incubate target cells at 37oC
Day 5: Collect Second Round of Virus
1.
2.
3.
4.
5.

Collect virus media from packaging cells into a conical and discard cells
Filter virus media through a 0.45 micron PVDF filter
Add equal volume of complete media to filtered virus media
Freeze at -80oC for use in day 6
Replace virus media on target cells with fresh media and passage if confluent

Day 6: Re-Infect Target Cells
1. Thaw virus media from day 5 and add 8 µg/mL of hexadimethrinebromide
2. Pipette 4 mL of virus media solution per plate to target cells
3. Incubate target cells at 37oC
Day 7: Replace Target Cell Media
1. Replace virus media on target cells with fresh media and passage if confluent
Day 8+: Selection
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1. Select for infected cells by adding puromycin to media (SKOV3=0.5 µg/mL,
HEY=1.0 µg/mL)
2. After 5 days of selection, cells which have been successfully infected should
begin proliferating
3. After selection, continue treatment of 0.2 µg/mL puromycin for maintenance

Wound healing assay
1.
2.
3.
4.
5.
6.
7.
8.

Plate 3 x 105 cells per well in a 6-well plate
Treat with 1 µg/mL of doxycycline for HSF1 KD inducible cells or leave untreated
Incubate for 48 hours at 37oC
Create 2 vertical and 2 horizontal lines in the confluent cells with a 2 µL pipette
tip
Wash cells with 1X PBS
Add 5 mL media without additives
Photograph the cells immediately and then again after 12 hours with an EVOS
inverted microscope (Advanced Microscopy Group)
Calculate would closure with TScratch software

Cell migration assay
1. Treat cells with 1.0 µg/mL of doxycycline for HSF1 KD inducible cells or leave
untreated
2. Incubate at 37oC for 48 hours
3. Remove media, wash with 1X PBS, and replace with media containing no
additives
4. Incubate at 37oC for 24 hours
5. Wash with 1X PBS, add trypsin to un-adhere the cells, and resuspend in
additive-free media
6. Add 2.5 x 104 cells to the upper portion of the Boyden chamber
7. Pipette 400 µL of complete media to the lower chamber
8. Incubate at 37oC for 16 hours
9. After incubation, remove cells on the upper chamber surface with a cotton swab
10. Fix and stain cells on the lower chamber surface with 1% (w/v) crystal violet in
methanol
11. Count cells in 10 random fields of view from each well
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Appendix B: Gene set enrichment analysis. Provided are the total number of entities
within a network, expanded and measured entities in the pathway, enrichment scores,
median fold change of the network, and the p-value. Also provided is the Gene Set
Category.
Name

Total
Entities

Expanded
Entities

Measured
Entities

Enrich.
Score

Normal.
ES

Median
change

p-value

Gene Set
Category

Actin Cytoskeleton Regulation

51

551

528

0.31765

1.26305

1.01748

0.01078

AGER -> NF-kB signaling

14

34

33

0.52429

1.46053

1.06437

0.0293

Axon Guidance

58

1051

983

0.27633

1.14787

1.01045

0.04988

Biosynthesis of CoA and holo-ACP

16

21

10

-0.6627

-1.4878

1.19956

0.05

Branched chain amino acids
metabolism

99

123

50

-0.6871

2.23849

1.35191

0

CCR2/5 -> STAT signaling

20

20

16

0.69406

1.58304

1.00347

0.01581

CCR5 -> TP53 signaling

17

17

13

0.69792

1.63466

-1.0087

0.01931

Cell cycle

140

585

483

0.30307

1.21387

1.05336

0.03704

CHRAC Chromating Remodeling

16

289

214

0.39429

1.46877

1.07923

0.0061

CSF2R -> NF-kB signaling

6

14

14

0.67175

1.58485

1.18509

0.02222

DDR1 -> NF-kB signaling

14

22

21

0.57985

1.4977

1.17283

0.0303

DNA Replication

29

134

119

0.39631

1.37964

1.08298

0.03333

EphrinR -> STAT signaling

15

15

15

0.62648

1.48748

1.15269

0.04724

Fatty acid oxidation

73

99

39

-0.552

1.64026

-1.1708

0

FibronectinR -> AP-1/ELKSRF/SREBF signaling

55

105

98

0.4226

1.43344

1.05885

0.03051
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FibronectinR -> NF-kB signaling

22

58

55

0.49258

1.51462

1.08298

0.03484

Folate biosynthesis

63

66

20

-0.6041

1.60545

1.30586

0

Glycogen metabolism

37

55

34

-0.5597

1.68753

1.12117

0.00413

Glycosylphosphatidylinositol(GPI)anchor biosynthesis

32

195

50

-0.5068

1.64655

1.13092

0

Gonadotrope Cell Activation

71

728

688

0.32639

1.32513

1.03526

0

Hedgehog Pathway

17

626

581

0.33211

1.32792

1.05702

0.00272

Histone Acethylation

33

329

262

0.36642

1.38583

1.05702

0.01176

Histone and DNA Methylation

37

352

273

0.36652

1.39196

1.05885

0

Histones Sumoylation

25

252

201

0.40564

1.48278

1.09051

0

Histones Ubiquitylation

23

334

267

0.44031

1.67112

1.12506

0

IGF1R -> ELKSRF/HIF1A/MYC/SREBF signaling

23

46

43

0.52628

1.51745

1.26138

0.02555

IL6R -> CEBP/ELK-SRF signaling

18

24

24

0.64418

1.66813

1.36841

0

INO80 Chromating Remodeling

25

449

365

0.32253

1.25759

1.05702

0.02571

Insulin Action

50

912

840

-0.2518

1.12304

-1.0299

0.02885

LeptinR -> ELK-SRF signaling

16

22

22

0.61225

1.55556

1.36841

0.01852

Lysine metabolsm

84

139

58

-0.4593

1.50721

1.18304

0.01869

MacrophageR -> CEBPB/NF-kB
signaling

21

43

42

0.49483

1.46306

1.06992

0.04348

Malonate, propanoate and betaalanine metabolism

99

121

53

-0.4545

1.46122

1.08862

0.0177
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Mast Cell Activation

64

558

514

0.36922

1.48169

1.01045

0

Metabolism of glucocorticoids and
mineralcorticoids

75

85

18

0.77862

1.96404

1.04972

0

Metabolism of
glycerophospholipids and ether
lipids

152

492

223

-0.3425

1.36331

1.06437

0

Ariadne
Metabolic
Pathways

Mevalonate pathway

40

44

18

-0.5792

1.48262

1.16675

0.04641

mRNA Transcription and
Processing

49

391

313

0.35818

1.3867

1.07549

0.00292

N-Glycan biosynthesis

76

215

82

-0.4706

1.63392

1.10191

0

Nicotinate and nicotinamide
metabolism

54

146

35

-0.5403

1.59015

1.15669

0.01852

Ariadne
Metabolic
Pathways
Ariadne
Cell
Process
Pathways
Ariadne
Metabolic
Pathways
Ariadne
Metabolic
Pathways

NK Cell Activation

59

539

495

0.35242

1.39815

1.00696

0

Notch Pathway

40

1487

1375

0.27811

1.16303

1.00521

0.02564

NURD Chromating Remodeling

31

307

222

0.38026

1.39857

1.06253

0.00292

NURF Chromating Remodeling

17

288

207

0.39264

1.45065

1.06253

0.00904

PECAM -> SP1 signaling

12

18

18

0.69123

1.67127

1.36841

0.01792

Phenylalanine and Tyrosine
metabolism

130

161

56

-0.4499

1.46545

1.08862

0.02315

PTAFR -> NF-kB signaling

22

63

57

0.47289

1.41304

1.12896

0.03915

PTPRC -> BCL6 signaling

21

27

24

0.6188

1.59146

1.17691

0.01111

ROS metabolism

43

72

35

0.61282

1.71224

1.00347

0.00699

Skeletal Myogenesis Control

70

589

555

0.29613

1.19784

1.03886

0.02997

Sphingolipid metabolism

86

322

119

-0.4111

1.53622

1.06622

0

SRCAP Chromating Remodeling

20

284

213

0.3977

1.44951

1.07923

0.00904
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SWI/SNF BRG1/BAF Chromating
Remodeling

25

284

210

0.39355

1.46011

1.07549

0.00304

SWI/SNF BRG1/PBAF Chromating
Remodeling

26

285

211

0.39264

1.45068

1.06253

0.00617

T Cell Activation

80

957

794

0.32951

1.34745

1.00347

0

ThrombopoietinR -> SP1 signaling

12

18

18

0.63547

1.49265

1.35191

0.01538

TLR4/5/7/9 -> NF-kB signaling

19

27

23

0.56954

1.47303

1.07363

0.03008

TNFR -> AP-1/ATF/TP53 signaling

40

40

38

0.57226

1.64605

1.16473

0.00346

TNFR -> CREB/ELK-SRF signaling

42

45

43

0.53299

1.59125

1.16473

0.01695

TNFR -> NF-kB signaling

32

40

38

0.61455

1.76894

1.12896

0.0034

TNFRSF1A -> AP-1/ATF/TP53
signaling

30

36

34

0.63831

1.77934

1.27456

0

TNFRSF1A -> CREB/ELK-SRF
signaling

32

41

39

0.60603

1.75651

1.29012

0.00353

TNFRSF6 -> HSF1 signaling

15

15

15

0.67724

1.59139

1.25266

0.00781

Translation Control

86

1012

922

0.27908

1.15021

1.02633

0.03874

Tryptophan metabolism

112

326

135

-0.465

1.72372

1.10957

0

Ubiquitin-dependent Protein
Degradation

15

125

100

0.5559

1.84663

1.32869

0

VasopressinR1 -> STAT signaling

16

50

45

-0.4917

1.50595

1.09809

0.02791

VEGFR -> NFATC signaling

26

37

31

0.60393

1.72553

1.12896

0.00733

Vitamin B5 (pantothenate)
metabolism

24

29

9

0.77523

1.64224

1.06069

0.0155
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Appendix C: Complete list of sub-networks that are related to the response to stress,
the DNA methylation pathway and the histone acetylation pathway.
Name

Type

chromosome
condensation

Cell Process

330

2.4751

2

2

0

chromatin
remodeling

Cell Process

1017

8.2821

3

3

0

EP300

Protein

E1A binding protein p300

KAT2B

Protein

K(lysine)
acetyltransferase 2B

transcription
initiation

Cell Process

SIRT1

Protein

sirtuin 1

844

MECP2

Protein

NCOA1

Protein

BRCA1

Protein

NCOA3

Protein

CREBBP

Protein

methyl CpG binding
protein 2 (Rett
syndrome)
nuclear receptor
coactivator 1
breast cancer 1, early
onset
nuclear receptor
coactivator 3
CREB binding protein

histone H3

Functional
Class
Functional
Class

histone
deacetylase

Description

Connec
tivity

Probe
Value

Inde
gree

Outde
gree

1503

1.1627

5

1

4

406

1.3732

4

1

3

2

2

0

2.3254

6

1

5

343

1.4845

2

0

2

414

5

0

5

3

0

3

468

1.2592
1.1507
8.4708

3

0

3

813

2.254

3

0

3

1267

1.0943

8

7

1

2000

3.1766

9

5

4

754

2.1886

4

0

4

278

858

histone
acetyltransfer
ase
HDAC2

Protein

histone deacetylase 2

461

2.0314

1

0

1

KAT5

Protein

290

0

2

Protein

890

1.3059
1.6818

2

HDAC1

K(lysine)
acetyltransferase 5
histone deacetylase 1

5

0

5

histone H4

Functional
Class
Cell Process

506

1.0122

5

5

0

42

1.7441

1

1

0

Complex

125

2.2153

2

0

2

190

8.2821

1

1

0

NCOR2

Functional
Class
Protein

376

2

0

2

NCOR1

Protein

2

0

2

RBBP4

Protein

128

1.1728
1.2746
1.3566

1

0

1

SIN3A

Protein

156

1.4439

6

0

6

KAT2A

Protein

287

1

0

1

SAP30

Protein

1.9725
3.0367

1

0

1

protein
nucleus
import
NuRD
complex
histone H2B

Functional
Class

Local
Connectivity

nuclear receptor
corepressor 2
nuclear receptor corepressor 1
retinoblastoma binding
protein 4
SIN3 homolog A,
transcription regulator
(yeast)
K(lysine)
acetyltransferase 2A
Sin3A-associated
protein, 30kDa

423

231

124

histone H2A
KPNA2

Functional
Class
Protein

RBBP7

Protein

SAP18

Protein

trichostatin A

Small
Molecule
Small
Molecule

sodium
butyrate

172
karyopherin alpha 2
(RAG cohort 1, importin
alpha 1)
retinoblastoma binding
protein 7
Sin3A-associated
protein, 18kDa

2.1697

343

125

3

3

0

2

1

1

80

1.0886

2

0

2

19

2.7274

2

0

2

1

1

0

1

1

1

0

1

